HomeMy WebLinkAboutDEQ-CFW_00001669FINAL
STUDY TITLE
Ammonium Perfluorooctanoate:
Phase II. Retrospective Cohort Mortality Analyses
Related to a Serum Biomarker of Exposure in a Polymer Production Plant
AUTHOR: Robin C. Leonard, Ph.D.
STUDY COMPLETED ON: September 15, 2006
PERFORMING LABORATORY: DuPont Epidemiology Program
DuPont Haskell Laboratory for Health and Environmental
Sciences
1090 Elkton Road, Newark, DE 19714
LABORATORY PROJECT ID: DuPont-14809 (Phase II)
WORK REQUEST NUMBER: 15259
SERVICE CODE NUMBER: 1242
SPONSOR: E.I. du Pont de Nemours and Company
Wilmington, Delaware 19898
U.S.A.
I of 73 (c) Copyright 2006 E.I. du Pont de Nemours and Company. All Rights Reserved No portion of this work may be reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001669
FINAL
Good Epidemiology Practice Compliance Statement................................................................ 5
DuPontApproval......................................................................................................................... 6
EpidemiologyReview Board........................................................................................................ 7
Abbreviationsand Symbols......................................................................................................... 8
ExecutiveSummary...................................................................................................................... 9
Introduction................................................................................................................................. 11
Methods........................................................................................................................................ 12
CohortAscertainment............................................................................................................ 13
DuPontMortality Registry..................................................................................................... 13
ExposureCategorization........................................................................................................ 13
Establish Job Exposure Categories....................................................................................... 14
Exhibit 1. Group changes based on similar job titles........................................................... 15
Application of Job Exposure Categories to Historical Job Titles ......................................... 16
Calculation of Individual Exposure Metrics......................................................................... 16
Exhibit 2. Example of calculation of average intensity of exposure* ................................. 16
Validate Exposure Classification.......................................................................................... 16
Exhibit 3 Etiology of Validation Data Set ............................... .................................... I........ 17
Exhibit 4. Results of mixed model used to validate cumulative exposure to PFOA: serum
PFOA as a function of estimates of PFOA exposure based on job ..................................... 18
Exhibit 5. Validation of exposure using repeated measurements (mixed model) to predict
serumPFOA.......................................................................................................................... 19
Mortality Analyses and Development of Occupational Reference Files ............................ 19
Cox Proportional Hazards Modeling.................................................................................... 20
Description of Methods Specific to Ischemic Heart Disease ................................................ 21
Categories of exposure for average intensity: ....................................................................... 21
Exhibit 6. Average intensity of exposure categories for proportional hazards analyses for
ischemic heart disease mortality, stratified by exposure lag period ..................................... 22
Categories of exposure for cumulative exposure.................................................................. 23
Exhibit 7A. Cumulative exposure categories for proportional hazards analyses for ischemic
heart disease mortality, stratified by exposure lag period; quartiles determined by
cumulative exposure distribution of cases among white males ............................................ 23
Exhibit 7B. Cumulative exposure categories for proportional hazards analyses for ischemic
heart disease mortality, stratified by exposure lag period; quartiles determined by
cumulative exposure distribution of entire cohort ................................................................ 24
Results.......................................................................................................................................... 25
CohortDescription.................................................................................................................. 25
Mortality Analyses on Entire Cohort.................................................................................... 25
AllCauses of Death.............................................................................................................. 26
AllMalignant Neoplasms..................................................................................................... 26
Cancer of Biliary Passages and Liver...................................................................................
26
Cancerof Pancreas................................................................................................................ 26
UrinaryTract Cancers........................................................................................................... 27
Cancer of Bronchus, Trachea, Lung..................................................................................... 27
Cancerof Prostate................................................................................................................. 27
CerebrovascularDisease....................................................................................................... 27
AllHeart Disease.................................................................................................................. 28
IschemicHeart Disease......................................................................................................... 28
2 of 73 (c) Copyright 2006 E.I. du Pont de Nemours and Company. All Rights Reserved. No portion of this work may be reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001670
FINAL
DiabetesMellitus.................................................................................................................. 28
Cox Proportional Hazards Modeling.................................................................................... 28
IschemicHeart Disease......................................................................................................... 28
Discussion..................................................................................................................................... 29
Conclusions.................................................................................................................................. 32
References.................................................................................................................................... 33
TABLES....................................................................................................................................... 36
Table 1 Washington Works mortality study cohort............................................................ 37
Table 2 SMRs for selected causes of death in Washington Works males, females
compared to DuPont Region 1 (West Virginia (less Washington Works), Ohio, Virginia,
Kentucky, Indiana, Pennsylvania, Tennessee, and North Carolina), U.S.A. national
population, West Virginia state population.......................................................................... 38
Table 3 White male workers included in the risk -sets of the proportional hazard analysis
for IHD stratified by case/non-case status............................................................................ 39
Table 4 White male workers included in the risk -sets of the proportional hazard analysis
stratified by never-APFO-use/ever-APFO-use status.......................................................... 40
Table 5 Mortality rate ratios for IHD by exposure category for no -lag analyses using case
calendar -year and year of hire (pre-1954) as potential confounders ................................. 41
Table 6 Mortality rate ratios for IHD by average intensity exposure category, including
increasing 5-year lags of exposure, using case calendar -year and year of hire (pre-1954)
aspotential confounders......................................................................................................... 42
Table 7 Mortality rate ratios for IHD by cumulative exposure category, including
increasing 5-year lags of exposure, using case calendar -year and year of hire (pre-1954)
as potential confounders; A) exposure categories based on case distribution, B) exposure
categories based on cohort distribution................................................................................ 43
FIGURES..................................................................................................................................... 44
Figure 1. Time in Job vs Serum PFOA—Cross-Sectional Study --Job Exposure Category 1
................................................................................................................................................... 45
Figure 2. Time in Job vs Serum PFOA—Cross-Sectional Study —Job Exposure Category 2
............................................................................................................................................. 46
Figure 3. Time in Job vs Serum PFOA—Cross-Sectional Study —Job Exposure Category 3
................................................................................................................................................... 47
Figure 4. Serum PFOA vs Cumulative Exposure - FLAIR Data ..................................... 48
Figure 5. Serum PFOA vs Average Intensity of Exposure - FLAIR Data ....................... 49
Figure 6. Serum PFOA vs Concurrent Job Intensity Factor - FLAIR Data ................... 50
Figure 7. Decreasing IHD mortality rates in the U.S.A. ..................................................... 51
APPENDICES............................................................................................................................. 52
Appendix A Washington Works vs Region 1..................................................................... 53
All -Cause Mortality Surveillance Report: Males................................................................ 53
All -Cause Mortality Surveillance Report: Females............................................................. 55
All -Cause Mortality Surveillance Report: Totals (Males and Females) ............................... 57
Appendix B Washington Works vs USA............................................................................ 59
All -Cause Mortality Surveillance Report: Males................................................................ 59
All -Cause Mortality Surveillance Report: Females............................................................. 61
All -Cause Mortality Surveillance Report: Totals (Males and Females) .............................. 63
Appendix C Washington Works vs West Virginia............................................................ 65
All -Cause Mortality Surveillance Report: Males................................................................ 65
All -Cause Mortality Surveillance Report: Females............................................................. 67
3 of 73 (c) Copyright 2006 E.I. du Pont de Nemours and Company. All Rights Reserved. No portion of this work may be reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of Dupont.
DEQ-CFW 00001671
FINAL
All -Cause Mortality Surveillance Report: Totals (Males and Females) .............................. 69
AppendixD.............................................................................................................................. 71
Job Exposure Category Development based on Division and Job ....................................... 71 -
4 of 73 (c) Copyright 2006 E.I. du Pont de Nemours and Company. All Rights Reserved No portion of this work may be reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission ofDuPont.
DEQ-CFW 00001672
1�:7i
Good Epidemiology Practice Compliance Statement
This study was conducted according to guidance provided by the American College of
Epidemiology Ethics and Standards Practice Committee which can be accessed at
http://www.acepidemiology2.org/policystmts/EthicsGuide.asp.
Applicant / Sponsor: E.I. du Pont de Nemours and Company
Wilmington, Delaware 19898
U.S.A.
ilvDAM
EP_
5 of 73 (c) Copyright 2006 E.I. du Pont de Nemours and Company. All Rights Reserved No portion of this work maybe reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001673
FINAL
DuPont Approval: We, the undersigned, declare that this report provides an accurate evaluation
of data obtained from this study.
F �
} w J a a'" -rl
l-'y
Okkmaiams
Pff-w-Vir
}
AproWd bur
-
Chu
„, 1 ,
€,db.- `
6 of 73 (c) Copyright 2006 E.I. du Pont de Nemours and Company. All Rights Reserved No portion ofthis work may be reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission ofDuPont.
DEQ-CFW 00001674
FINAL
Epidemiology Review Board
rr-"�hzat�i���k���attatc°.a��l��,�::��.
Cowan -is
)
�E
•='ti
# Li
h �
Each ERB member was asked to sign off on this report using their own separate signature page,
and then to fax their signature to the DuPont Epidemiology Department. Once received by the
DuPont Epidemiology department, each fax was then scanned into the computer system as jpeg
files. The jpeg files were then cropped to display only the signature. Each cropped image was
then inserted into this page, using Microsoft Word. The original faxes will be retained in the
DuPont archives.
7 of 73 (c) Copyright 2006 E.I. du Pont de Neawurs and Company. Ali Rights Reserved No portion of this work maybe reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001675
FINAL
Abbreviations and Symbols
AIC
Akaike Information Criterion, a partial likelihood test statistic
APFO
Ammonium perfluorooctanoate
BMI
Body mass index
CI
Confidence interval
CPHM
Cox proportional hazards model
CSHS
Cross -sectional health survey
FLAIR
Fluoropolymers Laboratory Analysis Information Retrieval
GI
Gastrointestinal
HDL
High -density lipoprotein
HWE
Healthy worker effect
HWSE
Healthy worker survivor effect
IHD
Ischemic heart disease
LDL
Low -density lipoprotein
MRR
Mortality rate ratio
NDI
National Death Index (USA)
OCMAP
Occupational Mortality Analysis Program® (University of Pittsburgh)
PFOA
Perfluorooctanoic acid
PPE
Personal protective equipment
PPM
Parts per million
PPM-Years
Parts per million per year, accumulated
SMR
Standardized mortality ratio
VLDL
Very low -density lipoprotein
8 of 73 (c) Copyright 2006 E.I. du Pont de Nemours and Company. All Rights Reserved No portion of this work may be reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001676
FINAL
Executive Summary
Ammonium perfluorooctaonate (APFO) is the ammonium salt of the fully fluorinated, 8-carbon
carboxylic acid. APFO is used to aid in the emulsion polymerization of fluoropolymers. APFO
and its salts are soluble in water and readily dissociate to the perfluorooctanoate anion (PFOA).
APFO is a surfactant that enables the fluoropolymer components to remain emulsified during
polymerization and is not incorporated into the polymer itself. It is the ammonium salt (APFO)
to which workers may be exposed; the biomarker measured in serum is the dissociated anion
(PFOA).
As a result of the presence and biopersistence of PFOA in the blood of humans, the potential
health effects of the chemical have been examined, primarily in occupational cohorts. The plant
site where this study was conducted comprises several businesses with a diverse range of
polymer manufacturing processes, most of which do not involve the use of APFO.
Approximately one-half of the employees at the site have been assigned to APFO areas at some
time in their careers. As part of a large project on occupational exposure to PFOA, this study's
objective is to determine whether workplace exposure to PFOA is related to increased mortality
risk for any cause (Phase II).
The overall project comprised two studies: Phase I, a cross -sectional surveillance that analyzed
several types of clinical data (blood chemistries such as lipids, enzymes, and blood counts,
among others) and a biomarker of exposure (serum PFOA) for potential relationships (to be
issued in a separate report); and Phase II, a retrospective cohort study that examined site -wide
standardized mortality analyses, and also utilized job history information as well as serum PFOA
data to classify each member of the historical cohort by level of potential occupational exposure
for a more detailed analysis of ischemic heart disease. Based on the results of the cross -sectional
study, we concluded that workers in all areas across the entire plant site show some measurable
level .of serum PFOA (range: 0.005 ppm to 9.55 ppm).
The cohort for Phase II was defined as all individuals who have ever worked at the Washington
Works plant at any time between January 1, 1948 (plant start-up) and December 31, 2002. The
cohort (n = 6,027) was ascertained primarily through the DuPont Epidemiology Registries;
additional members were identified from plant -based work history records.
Standardized mortality ratios were calculated for the study cohort for all causes of death, death
from all cancers combined, and disease -specific causes of death by comparing the cohort to rates
for three reference populations: the general population of the U.S.A., the West Virginia general
population, and the population of DuPont workers residing in West Virginia and seven
neighboring states in the region (DuPont Region 1). In addition, Cox proportional hazards
models provided an internal comparison based on exposure categories of serum PFOA for
mortality due to ischemic heart disease.
Mortality rates at this site are generally well within expected values and support the presence of a
healthy worker effect. Analyses specific to PFOA categories were conducted for ischemic heart
disease mortality. The analyses based on average intensity of exposure showed no relationship
to PFOA exposure levels. The analyses based on cumulative exposure indicated an increasing
trend for the mortality rate ratio with increasing exposure category if those categories were based
9 of 73 (c) Copyright 2006 E.I. du Pont de Nemours and Company. All Rights Reserved. No portion of this work may be reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission ofDuPont.
DEQ-CFW 00001677
FINAL
on the distribution of case exposures, but not if those categories were based on the distribution of
exposures in the entire cohort. In no case were the mortality rate ratio estimates statistically
significant.
Prostate cancer and cerebrovascular disease, both reported as increased in previous 3M Company
occupational epidemiology reports [1,2], were reduced in this cohort against all reference
populations, cerebrovascular disease significantly so for the U.S.A. and West Virginia
populations. The few cases of each of these causes of death did not allow meaningful internal
comparisons.
Comparisons using DuPont Region 1 reference rates, but not U.S.A. or West Virginia rates, do
indicate statistically non -significant elevations in SMRs for kidney cancer mortality (SMR=185;
95% CI=95-323, p>0.05), and a statistically significant increase in diabetes mortality
(SMR=197; 95% CI=123-298, p<0.05) in males and females combined at this plant site. While
few kidney cancer cases had been employed in APFO areas, the data from this study are
inadequate for examining in appropriate detail rare outcomes such as kidney cancer. Similarly,
the difficulties in examining mortality for diabetes prevent drawing conclusions based on these
data.
The results reported here show no convincing evidence of increased mortality risk associated
with APFO exposure for workers at this plant. These results do show statistically non -significant
elevations in relative risk for kidney cancer and a statistically significant increase in diabetes
mortality for workers at this site. However, given the size and length of follow-up of the study
population,'the evidence to thoroughly examine mortality events like kidney cancer or even
diabetes, may not be adequate. Proportional hazards analyses for ischemic heart disease mortality
showed an increase in the model based on equal distribution of cases across cumulative exposure
categories in one lagged analysis (the 10-year lag period). Other exposure lags showed no effect,
and results for a second set of models using a different set of exposure cutpoints were attenuated
toward the null. None of the hazard estimates themselves were statistically significant. Thus the
positive finding in the proportional hazard analysis, as well as the increased diabetes mortality,
might be due to chance. Because of the complexity of the exposure assessment and limited
power for some analyses, additional investigations are needed.
10 of 73 (c) Copyright 2006 E.I. du Pont de Nemours and Company. All Rights Reserved. No portion of this work my be reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission o£DuPont.
DEQ-CFW 00001678
FINAL
Ammonium Perfluorooctanoate: Phase II. Retrospective Cohort Mortality Analyses
Related to a Serum Biomarker of Exposure in a Polymer Production Plant
Introduction
Ammonium perfluorooctanoate (APFO) is the ammonium salt of a fully fluorinated carboxylic
acid, perfluorooctanoic acid (PFOA). APFO is used to aid in the emulsion polymerization of
fluoropolymers. The salts of PFOA are soluble in water and readily dissociate to the carboxylate
anion (PFOA). APFO is a process additive, i.e., it is the surfactant that enables the
fluoropolymer components to remain emulsified in order for polymerization to occur. Neither
APFO nor PFOA is incorporated into the fluoropolymer.
As a result of industrial use of APFO and biopersistence of PFOA in the blood of humans, the
potential health effects of APFO have been examined in multiple studies, primarily in
occupational cohorts [1-7]. A study of community exposure to PFOA was conducted to
determine the relationships between serum concentrations and exposure sources, and also to
examine the relationships between PFOA and hematologic and biochemical clinical markers.
This community study indicated that water, not air, was the likely source of exposure; no
associations were seen with adverse health effects [8-9]. Some general population samples have
been used to examine biomonitoring data that indicated that age, gender, and possible duration of
exposure had little to do with the background levels in the population. [10-12].
A retrospective cohort mortality study was conducted at a 3M plant in Cottage Grove,
Minnesota, that produced APFO [1]. The cohort consisted of 3,537 workers employed for at least
six months between January 1947 and December 1983. Follow-up was nearly complete (99.5%)
for the study participants, and 398 deaths were recorded. Since APFO production was limited to
the Chemical Division, the two exposure categories were "exposed" (worked at least one month
in the Chemical Division) and "not exposed" (worked one month or less in the Chemical
Division).
Standardized mortality ratios (SMRs) were calculated comparing the Cottage Grove cohort with
mortality rates for the populations of the U.S.A. and the state of Minnesota, using stratification
for duration of employment and 3 exposure latency periods. When exposure status was taken
into account, most SMRs were significantly lower than the expected rate, a not surprising
finding, considering the potential for healthy worker bias. The SMR for prostate cancer was
elevated in the Chemical Division (area of APFO production), but this increase was not
statistically significant as it was based on only four cases. Internal comparisons were performed
using proportional hazards modeling for various categories of causes of death, including prostate
cancer. The only mortality rate ratio that was statistically significantly greater than 1.0 was for
the association between prostate cancer and duration of work in the Chemical Division.
However, given that there were only four cases in the Chemical Division and an additional two
cases in the rest of the cohort, it is difficult to emphasize this finding.
This study was updated through 1997; the updated cohort consisted of 3,992 workers who had
worked for at least one year at the Cottage Grove Plant. [2] The exposure categories were
changed to comprise three groups: "definite" (based on tasks performed in the Chemical
Division); "probable" (tasks involving transient, lower exposures); and "non -exposed" (primarily
non -Chemical Division jobs). A few SMRs were elevated: cancer of the prostate (N=1;
I I of 73 (c) Copyright 2006 E.I. du Pont de Nemours and Company. All Rights Reserved. No portion of this work may be reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001679
FINAL
SMR=1.30, 95% Cl: 0.03-7.20); pancreatic cancer (N=1; SMR=1.34, 95% Cl: 0.03-7.42);
and cerebrovascular disease (N=5; SMR=2.58, 95% Cl: 0.84-6.03); but none were statistically
significant, and all elevated SMRs were based on very few cases.
The DuPont Epidemiology Program conducted a cross -sectional health survey (Phase 1) of 1,025
employees at the Washington Works, West Virginia polymer production facility. That
investigation used epidemiologic and statistical analyses of several types of clinical data and a
biomarker of exposure (serum PFOA) to determine the presence of any association between
occupational exposure to APFO and measurable changes in clinical laboratory measurements or
physical examination endpoints. The results of this study indicated a positive association
between serum level of PFOA in workers at the polymer production plant and serum cholesterol,
triglycerides, and LDL cholesterol. No association was seen with HDL cholesterol [3]. These
results were similar to those published by Olsen et al. [4] from a cross -sectional study on 3M
workers at two plants. After adjustment for potential confounders including body mass index
(BMI), current alcohol use, smoking, and age, a statistically significant association between
increased serum levels of PFOA and increased levels of both cholesterol and triglycerides were
observed in multivariable linear regression analyses. Longitudinal analyses for the 3M workers
also showed that PFOA was positively associated with serum cholesterol (log -linear regression
coefficient = 1.03; 95% Cl: 1.01-1.05) and serum triglycerides (log -linear regression
coefficient = 1.10; 95% Cl: 1.05-1.16). However, as in our own study, the percent of variation
explained by the model, as well as by serum PFOA, was small, and there was no association of
serum PFOA with HDL cholesterol. The 3M investigators had concluded that since their results
were opposite to those expected based on animal studies, their findings were probably spurious.
DuPont conducted a cross -sectional medical surveillance for altered liver function on the
workers at the Washington Work plant site in 1979. These results indicated no changes in levels
of liver enzymes associated with work area assignment [5]. Gilliland and Mandel examined
clinical chemistries in 3M workers and reported no abnormalities or associations with total
organic fluorine levels [6]. They did suggest that serum total organic fluorine levels might
modulate hepatic responses to obesity and alcohol, but this suggestion was not supported by
results of subsequent surveillance examinations among those workers [7].
The current study examines all -causes of death combined and cause -specific mortality rates for
the DuPont employees at the Washington Works, West Virginia, polymer manufacturing facility.
This facility produces several types of polymers, most of which are made by processes not
involving APFO. Approximately one-third of the employees at the plant works in APFO-using
areas. SMRs were calculated by using three different reference populations: the general U.S.A.
population, the state population of West Virginia, and an eight -state regional DuPont employee
population (DuPont Region 1). Because increased lipids levels are a risk factor for
cardiovascular diseases, we also used Cox proportional hazards models to estimate mortality rate
ratios (MRR) for an internal comparison of mortality due to ischemic heart disease associated
with categories of exposure to APFO. The exposure assessment for PFOA was based on a
combination of work history information for each subject and serum PFOA levels obtained from
the Phase I cross -sectional survey of the active workers in 2004.
Methods
12 of 73 (c) Copyright 2006 ES du Pont de Nemours and Company, Al] Rights Reserved. No portion of this work maybe reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001680
FINAL
Cohort Ascertainment
The cohort was defined as all individuals who -have ever worked at the Washington Works plant
at any time between January 1, 1948 (plant start-up) and December 31, 2002. The cohort was
ascertained primarily through the DuPont Epidemiology Registries; additional members were
identified from plant -based work history records.
DuPont Mortality Registry
The DuPont Company has maintained a Mortality Registry for all active and pensioned U.S.A.
employees since 1957. This Registry provides the expected numbers of deaths used in the
DuPont Epidemiology Surveillance Program SMR calculations to compare each plant site in the
U.S.A. to the rest of the U.S.A. DuPont population. Deaths are reported to the Registry by the
corporate Benefits division through death certificates that accompany life insurance claims filed
by beneficiaries of deceased employees and pensioners. Until recently, employment duration of
at least 15 years was required for pensioning. However, additional changes in vesting strategies
and insurance policies created fiduciary responsibility on the part of the Company that requires
notification of death of additional former employees. Deaths are ascribed to the observed
numbers for the plant site at which the employee worked at the time of death, or the site at which
the pensioner worked at the time of retirement. For those who left the Company between 1950
and 1979, 91.7% were either pensioned or covered by some other vested benefit. Of the
employees leaving the company between 1980 and 2005, only 60% were pensioned or covered
by other vested benefits. However, deceased non -pensioned employees terminating after 1979
have been added to the Registry through the use of the National Death Index database, NDI Plus.
In addition, the social security numbers for each cohort member were submitted to the Social
Security Administration for confirmation of vital status.
The Employee Registry, which provides the demographic information on all individuals ever
employed by DuPont in the United States, is updated from a monthly upload from Corporate
Human Resources. The Epidemiology Employee Registry currently includes approximately
265,000 individuals, 6,027 who ever worked at Washington Works, approximately 2000 of
whom are presently located at that site.
Exposure Categorization
While the half-life of PFOA in humans is estimated to be about 4 years [13], the kinetics of
PFOA in humans are not well characterized. APFO can be absorbed via inhalation, as well as
orally and dermally. Dermal absorption is very slow, and is an issue only for occupational
exposure [14,15]. Serum PFOA levels were considered the best measure of exposure, because
serum levels integrate all routes of exposure and provide an estimate of the amount of the
compound delivered internally to the organ tissues. Information regarding the relationship
between an individual's job and the measured serum PFOA level was based on the Phase I cross=
sectional health survey conducted in 2004 and incorporated into the exposure assessment for the
retrospective cohort mortality study. There were four major steps in determining exposure
categories in Phase 1.
13 of 73 (c)Copyright 2006 E.I. du Pont de Nemours and Company. All Rights Reserved. No portion of this work maybe reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001681
FINAL
1) Establish relative exposure categories for current job titles using serum PFOA.
a. Link individually measured serum PFOA levels measured with the job title held
- by the individual at the time of sampling.
b. Examine the median, range, and distribution of serum levels for each job to
determine the typical exposure for that job title.
c. Based on the "typical" exposures, assign each job title to one of three relative
exposure categories (Job Exposure Category: low, medium, high).
2) Apply Job Exposure Categories to historical job titles.
a. Link unique job titles from work history files with job titles and assign the historic
job titles to the corresponding Job Exposure Category.
b. Apply appropriate Job Exposure Category to each record in the cohort work
history.
3) Calculate individual exposure metrics
a. Multiply the time each individual spent in each Job Exposure Category by the
intensity factor associated with that category and sum across all categories to
calculate individual Cumulative Exposure.
b. Calculate Average Intensity by dividing cumulative exposure by duration of hire.
4) Validate exposure classification by plotting exposure variables (average exposure
intensity, cumulative exposure, and concurrent job intensity factor) versus the measured
serum PFOA levels collected as part of a plant -site voluntary biomonitoring program
Establish Job Exposure Categories
Exposure and employment data were collected for 1,025 Washington Works employees as part
of the Phase I cross -sectional health survey conducted in 2004. These data were combined to
establish exposure categories for job titles. In the cross -sectional study, work divisions at the
plant site were designated as "APFO-use" or "no APFO use" based on the potential for exposure
to APFO, with the understanding that some individuals within APFO-use divisions may not have
had exposure to APFO and some individuals in no APFO-use divisions may have had
undocumented exposure to APFO.
Median, minimum, and maximum serum PFOA levels were calculated for each no APFO-use
division, using only individuals who had never worked in an APFO-use division, to establish the
criteria for the low -intensity job exposure category. Next, the median, minimum, and maximum
serum PFOA levels were calculated for each job title in the APFO-use divisions. The divisions
designated as "APFO-use" Divisions included: TEFLON® Maintenance, TEFLON Polymers
Production, TEFLON Copolymers Production, Research, and Technical. The distribution of
serum PFOA levels within each job title was examined. See Appendix D.
APFO-use jobs were then grouped into three job -exposure categories based on job -specific
PFOA serum level information:
14 of 73 (c) Copyright 2006 E.L du Pont de Nemours and Company. All Rights Reserved. No portion of this work maybe reproduced in whole or in pan by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission ofDuPont.
DEQ-CFW 00001682
FINAL
Job Exposure Category 1 consisted of all no APFO-use division jobs, and APFO-use jobs
within the same serum level range as those employees who had never had a job
assignment in any APFO-use division--median<0.25 ppm.
Job Exposure Category 2 consisted of APFO-use jobs with a median serum level >0.25
ppm and <0.75 ppm.
Job Exposure Category 3 comprised all APFO-use jobs with a median serum level >0.75
ppm.
Some latitude was allowed in the use of median serum levels as the only criterion in the
assignment of a given job title to a job exposure category. In instances where a job title was
categorized differently than similar job titles as a result of a median serum value from a very
small sample, the job title was grouped with the similar job titles. (See Exhibit 1.)
Exhibit 1. GrouD changes based on similar iob titles
Job
Exposure
Serum PFOA
Category
Division
Job
Median
Min
Max
n
From
To
Reason
Moved to be in same category
APFO-USE@
as other "Specialists" (n=11)
COPOLYMERS
AREA
with similar exposure (Range:
PROD.
SPECIALIST
0.255
0.255
0.255
1
2
1
0.025-0.272)
Moved to be with other "Sr
APFO-USE@
Engineers" in Job Exposure
POLYMERS
SR
Category 2 (n= 8; Range: 0.097
PROD.
ENGINEER
0.765
0.412
1.59 1
4
3 1
2
— 0.576)
TECHNICAL
TECH SPEC
0.783
0.783
0.783
1
3
2
Moved to be with other
"Specialists" in Job Exposure
APFO-USE@
COPOLYMERS
Category 2 (n= 7; Range: 0.134
PROD.
TECH SPEC
1.46
1.46
1.46
1
3
2
— 1.28)
The resulting numbers of cross -sectional study participants with jobs in Job Exposure Categories
1, 2, and 3 were 784, 107, and 134, respectively. The mean serum levels within the respective
groups were 0.21, 0.43, and 1.69 ppm. Those mean serum levels served as the intensity factors
for the three Job Exposure Categories.
Because PFOA is believed to have a half-life of about 4 years in humans [13], the length of time
spent in the assignments used to define the Job Exposure Categories was examined to ensure that
the job titles would not be misclassified as a result of individuals with either very short or very
long stays in the job. Each participant's serum PFOA level was plotted against the time in the
concurrent job by Job Exposure Category. The resulting correlation indicated that time in job
was not strongly associated with serum PFOA level and should not substantially contribute to
misclassification of job titles.
15 of 73 (c) Copyright 2006 E.I. du Pont de Nemours and Company. All Rights Reserved. No portion of this work may be reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001683
FINAL
Application of Job Exposure Categories to Historical Job Titles
Complete job histories for all Washington Works employees were obtained via electronic files
from the Human Resources department at the plant site. In addition, historical work divisions
were designated as "APFO-use" or "no APFO-use" based on the potential for occupational
exposure to APFO. All historical job titles in the "no APFO-use" work divisions were assigned
to Job Exposure Category 1. Approximately 1600 unique "APFO-use" job titles were identified
in the work history files. Most of those unique job titles resulted from variations in spelling or
abbreviations, or division name changes for common job titles. Historic job titles were matched
with similar titles identified in the cross -sectional survey and assigned to the corresponding Job
Exposure Category.
Calculation of Individual Exposure Metrics
Cumulative exposure was calculated for each individual in the full cohort by multiplying time in
the various job exposure categories by the intensity factor associated with job exposure
categories I through 3, either 0.21, 0.43, or 1.69 ppm, respectively.
Average intensity was also calculated for each cohort member by dividing the individual's
cumulative exposure by their duration of hire, as shown in Exhibit 2 below.
Exhibit 2. Example of calculation of average intensity of exposure*.
Time in
Intensity
Exposure
Category
Factor
JobExpCatl
2.50
0.21
0.52
JobExpCat2
12.00
0.43
5.16
JobExpCat3
7.25
1.69
12.25
17.94 / 21.75
�r Int si
x
e
x�_
*Values are at end of follow-up
Validate Exposure Classification
To validate the assignment of Job Exposure Categories to historical job titles, relationships were
examined between calculated exposure values and measured PFOA serum levels in the Phase III
Longitudinal Study dataset [16] (see Figures 4, 5, and 6). The Longitudinal Study dataset was
comprised of sampling data for individuals with more than one sample from the Fluoropolymers
Laboratory Analysis Information Retrieval (FLAIR) biomonitoring database together with the
Phase I study. The FLAIR biomonitoring database archived serum PFOA data collected on a
voluntary basis to ensure the effectiveness of workplace controls. Samples had been collected
between 1979 and 2002.
16 of 73 (c) Copyright 2006 E.I. du Pont de Nemours and Company. All Rights Reserved. No portion of this work maybe reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001684
FINAL
Since the assignment of Job Exposure Categories to historical job titles was based on blood
PFOA measurements that were taken in Phase I, those values were removed for the validation
analysis. There were also 40 observations from the FLAIR database (corresponding to 23
employees) where the PFOA blood sample was taken after the employee had stopped working at
the plant. These 40 observations were also removed from the validation analysis. Our validation
was performed on dataset 6 as described in Exhibit 3.
Fxhibit 3 Etiology of Validation Data Set
Data
Date of
Number of
Number of
set
Collection
Participants
Observations
1
FLAIR database
1979-2002
891
1947
2
Cross -Sectional Study
2004
1025
1025
3
All FLAIR data and Cross-
1979-2004
891
2148
sectional data of FLAIR
participants
4
FLAIR and Cross -sectional
1979-2004
461
1718
participants with more than 1
measurement each
5
FLAIR and Cross -sectional
1979-2002
461
1517
participants with more than 1
measurement each minus the
Cross -sectional samples
6
FLAIR and Cross -sectional
1979-2002
451
1477
participants with more than 1
measurement each minus the
Cross -sectional samples and
retiree samples
Cumulative exposure, average intensity, and concurrent job intensity factor were calculated for
each individual up to the time of the sampling (from hire date to sample date). The relationships
between each serum PFOA value and the corresponding average intensity, cumulative exposure,
and concurrent job intensity factor were analyzed. There were 21 missing values for job
intensity factor and 6 missing observations for average intensity.
First, the observations were treated as being independent (although many employees had more
than one observation) and examined in a general linear model. Then the associations between
serum PFOA and the exposures of interest (average intensity, cumulative exposure, and
concurrent job intensity factor) were examined in mixed models.
17 of 73 (a) Copyright 2006 E.I. du Pont de Nemours and Company. All Rights Reserved. No portion of this work may be reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission ofDuPont.
DEQ-CFW 00001685
FINAL
Exhibit 4. Results of mixed model used to validate cumulative exposure to PFOA: serum PFOA
as a function of estimates of PFOA exposure based on job.
Correlation
Coefficient
P value
Average Intensity
0.40
<0.0001
Cumulative Exposure
0.36
<0.0001
Intensity Factor
0.39
<0.0001
Prior to fitting the mixed models, sample variograms were created for the outcome variable
(blood PFOA) to evaluate the serial correlation, the measurement error and the random effect for
each mixed model. The spatial power covariance structure was found to have the best fit for the
data and was therefore used. This structure allows the correlations between errors to be modeled
in such a way that two points that are close in time are more correlated than two points that are
further apart in time. This covariance structure is appropriate for unequally spaced
measurements, which was the case in our dataset since employees were having their blood PFOA
checked voluntarily and at different time intervals.
Each model included the exposure of interest (average intensity, cumulative exposure, or we
calculated the numbers of years since January 1, 1979 that would correspond to each calendar
date (example: (blood sample date -January 1, 1979)/365.25). An interaction term between the
exposure variable and the date variable was also added to the model.
All exposure variables were positively and significantly associated with the outcome (serum
PFOA), suggesting that historical job titles were properly categorized (see Exhibit 5). Time was
negatively associated with serum PFOA, supporting the observation that PFOA is reduced over
time. The model that gave the best fit was the mixed model that included the exposure variable
and the time variable, without the interaction term. The concurrent job intensity factor model had
the best fit for the data as suggested by the lowest fit statistic test. Therefore intensity factor
explains serum PFOA better than cumulative exposure and average intensity. This suggests that
concurrent exposure has greater influence on serum PFOA levels than past exposure and,
therefore, the use of concurrent measured serum levels to characterize job titles into relative
exposure categories is a valid approach for this compound despite the concerns around half-life.
18 of 73 (c) Copyright 2006 E.I. du Pont de Nemours and Company. tlll Rights Reserved No portion of this work maybe reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001686
FINAL
Exhibit 5. Validation of exposure using repeated measurements (mixed model) to predict serum
PFOA
A. Predictor variable: average intensity.
Coefficient p
Average intensity 0.899 <0.0001
Time * -0.036 0.0006
Fit statistic: AIC = 5445.7**
B. Predictor variable: cumulative exposure
Coefficient P
Cumulative exposure 0.0002 <0.0001
Time * -0.034 0.0014
Fit statistic: AIC = 5477.6 **
C. Predictor variable: intensity factor
Coefficient P
Intensity factor 0.796 <0.0001
Time * -0.036 0.0006
Fit statistic: AIC = 5407.8 **
* Time is calculated as number of years since 1979
** For AIC-(Akaike Information Criterion), the smaller value indicates better fit.
Mortality Analyses and Development of Occupational Reference Files
All SMRs were calculated using OCMAP (Occupational Mortality Analysis Program) developed
by the University of Pittsburgh [17]. This software compares observed numbers of deaths in the
study population to expected numbers of deaths based on rates for chosen reference populations
for specific gender, 5-year time, and 5-year age categories by cause of death. State and U.S.A.
reference rate files were acquired directly from the University of Pittsburgh.
Estimating relative risks by SMRs is a standard epidemiological approach to adjust for
confounding by age and other characteristics that differ between populations. Typically, the
general U.S.A. population is used as the reference group; however, it is not an appropriate
comparison group for a worker cohort. Because healthier people are selectively hired to work,
these populations may not be comparable in terms of health status. This may introduce a
downward bias in estimates of the SMR due to confounding by the healthy worker effect [18-
20]. While the effect is generally stronger for chronic diseases, the downward bias in
comparative estimates has also been demonstrated for cancer [21].
One approach for reducing healthy worker bias is to choose a reference population composed of
workers unexposed to the particular hazardous agent of interest. Restricting the comparison
group to the same geographical region as the exposed cohort also improves comparability by
19 of 73 (c) Copyright 2006 E.I. du Pont de Nomura and Company. All Rights Reserved. No portion of this work may be reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001687
FINAL
reducing likelihood of unmeasured confounding by commonly shared regional characteristics
such as diet and lifestyle. Preliminary results from our work on another large occupational cohort
indicated that the most appropriate comparison for occupational cohorts is the working
population of the same company drawn from the same region as the study plant site (manuscript
in preparation). Potentially biased estimates of reduced SMRs usually seen when comparisons
are made to general non -occupational populations are not observed using this comparison,
presumably because the healthy worker effect is reduced. Additionally, comparing mortality
rates for workers from the same general region adjusts for local socio-cultural factors, although
not all local effects are likely to be removed.
A second component of healthy worker bias arises from the healthy worker survivor effect
(HWSE). This bias is introduced when less healthy workers leave the workforce earlier than
healthy workers, thereby having no opportunity to accrue cumulative exposures as large as more
healthy workers. One approach that has been proposed to reduce this healthy worker survivor
effect, is to assign zero weight to exposures in the 5 to 10 years proximate to the date of death (or
diagnosis) in order to discount the effect of exposures during periods of time closer to the event
of interest [22-23].
For the DuPont employee comparisons, we created a DuPont regional reference file (DuPont
Region 1) that included all DuPont employees in West Virginia and seven neighboring states:
Ohio, Virginia, Kentucky, Indiana, Pennsylvania, Tennessee, and North Carolina (excluding
those employees at the Washington Works site). For the DuPont worker mortality rates, race
was not an adjustment variable. No follow-up methods or efforts additional to those used in
Registry ascertainment were applied to the cohort files.
The first level of cohort analysis was the calculation of SMRs for the entire Washington Works
cohort, with follow-up from 1948 to 2002, the last year for which the Registry has been updated
through NDI Plus. SMRs were calculated based on comparisons to the U.S.A. general
population, the state of West Virginia, and the DuPont Region 1 reference file.
Cox Proportional Hazards Modeling
SMRs are useful for comparing mortality between an exposed to an unexposed reference group.
However, in order to take full advantage of the exposure assessment for PFOA and examine
exposure -response relationships we turned to Cox models for one outcome—ischemic heart
disease. Cox proportional hazards models (CPHM), with age as the time metameter, were used to
estimate adjusted mortality rate ratios (MRRs) for ordinal PFOA exposure categories. These
categories were based on the cumulative exposure calculated for each member of the historical
cohort based on the categorization of jobs. The cumulative exposure thus calculated was then
used to derive the average exposure intensity for each cohort member, based on the job history
data. Ischemic heart disease mortality was chosen based on the fact that increased lipids are a
risk factor for ischemic heart disease, and there were sufficient cases to enable division into
exposure groups. For ischemic heart disease, we estimated mortality rate ratios using lagged
exposure (5, 10, 15, and 20 years) to reduce any bias introduced by the healthy worker survivor
effect.
20 of 73 (c) Copyright 2006 E.I. du Pont de Nemours and Company. All Rights Reserved. No portion of this work may be reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001688
FINAL
CPHM is a statistical model used to investigate the relationship between survival time (or time to
event) and one or more independent variables [24]. An assumption that must be met for these
analyses to be meaningful is that the hazard rates are proportional to one another at all ages.
This means that at any given age (t), the hazard rate for those exposed to a risk factor [h](t)] is a
constant multiple of the underlying hazard [ho(t)] for that age. A significant advantage to the
approach is that the baseline hazard function does not have to be explicitly described, since the
different risks are relative. The model can be stated as follows:
hi(t) = ho(t) X B
Estimating the constant multiplication factor for changes in risk (B) is conveniently done using
an exponential function, B = eb. Reformulating equation 1 yields
hl(t) = ho(t) X eb.
Therefore, if ho(t) represents the hazard in the unexposed group at any given time, the hazard
ratio (HR) comparing the exposed and unexposed is
HR = [h,(t)] / [ ho(t)] = eb, or taking logarithms, log(HR) = b.
All CPHM was conducted using SAS Proc PHREG, version 9.01.
Describtion of Methods Specific to Ischemic Heart Disease
There were only three cases of IHD among women and only one non -white male case.
Therefore, women and non -whites were excluded from all proportional hazards analysis.
Person -time for the risk set of each index case was comprised of people who had started working
by the age of the case that defined the risk set (case age at death), and were still alive at that age.
In addition to exposure to PFOA, the regression models also included calendar year of death in
order to control for secular trends over the follow-up period.
There were 235 cases of ischemic heart disease available for analysis. Since cases were hired on
average 20 years earlier than the non -cases, year of hire was also included to adjust for
confounding. Because half of the cases were hired before 1954, we created a binary variable for
year of hire (before or after 1954) that was included in the model. The correlation between
calendar year of death and the binary variable, hired pre- or post-1954, was — 0.44 (p<0.0001).
We chose to use average intensity and cumulative exposure as the exposure metrics for CPHM
analysis. Because heart disease mortality is known to be strongly affected by the healthy worker
survivor effect, we chose to lag both exposure metrics 5, 10, 15, and 20 years. These lags
eliminated the more recent exposures to reduce bias engendered by healthier workers staying in
the workplace longer periods of time thus accumulating more exposure.
Categories of exposure for average intensity:
In each Cox model, workers whose jobs were categorized as having the lowest exposure to
PFOA (lowest average intensity) and who also never worked in any APFO-using division were
considered the reference group, thus enabling an internal analysis. Both the APFO areas of the
plant site and the non-APFO areas comprise a wide diversity of jobs (mechanics, engineers,
supervisors, administrative, etc.) This diversity of job types in all non-APFO areas of the plant
21 of 73 (c) Copyright 2006 E.I. du Pont de Nemours and Company. All Rights Reserved. No portion of this work may be reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001689
FINAL
should make this group of workers comparable to those workers who ever worked with APFO in
all characteristics except for exposure to APFO.
Five categories of average intensity of exposure to APFO were specified to ensure that an
adequate number of cases would be in each category, thus increasing the stability of the MRR
estimates. The exposure categories are ordinal, with 0 comprising the reference group, 1 being
the lowest exposure, and 4 being the highest exposure category, for those analyses that
comprised four categories. These exposure category definitions are presented in Exhibit 6.
Exhibit 6. Average intensity of exposure categories for proportional hazards analyses for
ischemic heart disease mortality, stratified by exposure lag period.
No lag of exposure
N = 4,460
o Reference: x = 0.21 ppm and Never APFO-use 167 cases
o Category 1: x = 0.21 ppm and Ever APFO-use 28 cases
o Category 2: 0.21<x<= 0.250 ppm 12 cases
o Category 3: 0.250<x<=0.371 ppm 14 cases
o Category 4: > 0.371 ppm 14 cases
Exposure lagging 5 years
N = 4,440
o Reference: x = 0.21 ppm and Never APFO-use 162 cases
o Category 1: x = 0.21 ppm and Ever APFO-use 30 cases
o Category 2: 0.211 <= x <= 0.254 ppm 12 cases
o Category 3: 0.261 <= x <= 0.551 ppm 13 cases
o Category 4: 0.592 <= x <= 1.524 ppm 12 cases
Exposure lagging 10 years
N = 3,989
o Reference: x = 0.21 ppm and Never APFO-use
152 cases
o Category 1: x = 0.21 ppm and Ever APFO-use
30 cases
o Category 2: 0.211 <= x <= 0.256 ppm
11 cases
o Category 3: 0.261 <= x <= 0.555 ppm
12 cases
o Category 4: 0.565 <= x <= 1.524 ppm
12 cases
Exposure lagging 15 years
N = 3,986
o Reference: x = 0.21 ppm and Never APFO-use 142 cases
o Category 1: x = 0.21 ppm and Ever APFO-use 30 cases
o Category 2: 0.21 < x <= 0.269 ppm 11 cases
o Category 3: 0.269< x <= 0.591 ppm 12 cases
o Category 4: x > 0.591 ppm 12 cases
22 of 73 (c) Copyright 2006 E.I. du Pont de Nemours and Company. All Rights Reserved. No portion of this work may be reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001690
FINAL
Exposure lagging 20 years
N = 3,440
o Reference: x = 0.21 ppm and Never APFO-use 130 cases
o Category 1: x = 0.21 ppm and Ever APFO-use 28 cases
o Category 2: 0.21<x <= 0.330 ppm 16 cases
o Category 3: x > 0.330 ppm 15 cases
Categories of exposure for cumulative exposure
Cumulative exposure was estimated as the total attained exposure for each case event at the time
of death. Analytic strata were created for each case event by matching all eligible non -case
subjects (workers who had not died by the date of the case event) and assigning cumulative
exposure based on total attained exposure for each worker at the same age as the case event.
Given that there is debate on the implications of the statistical aspects of the categorization of
cumulative exposure, two different approaches were used to determine four cumulative exposure
categories. The two approaches thus provided a form of sensitivity analysis. In the first analysis
(exhibit 7A), quartiles of the cumulative exposure were determined by the distribution of
exposures for case subjects. In a second analysis designed to test the model sensitivity to
cumulative exposure categorization, quartiles were determined by the distribution of exposures
for all workers in the cohort (exhibit 7B). For each lagged analysis, the exposure values for the
four categories are shown for both strategies, and the number of cases of IHD mortality are
listed. Cox models analyzing the proportional hazards for cumulative exposure categories with
the lowest exposure group serving as the referent also included variables adjusting for calendar
year of the case event and pre-1954 hire period.
Exhibit 7A. Cumulative exposure categories for proportional hazards analyses for ischemic
heart disease mortality, stratified by exposure lag period; quartiles determined by cumulative
exposure distribution of cases among white males.
No lag of exposure
N = 4,460
o Reference: x <= 3.81 ppm years 58 cases
o Category 1: 3.81<x<= 5.45 ppm years 59 cases
o Category 2: 5.45<x<= 6.78 ppm years 59 cases
o Category 3: x>6.78 ppm years 59 cases
Exposure lagging 5 years
N = 4,440
o Reference: x <= 3.42 ppm years 57 cases
o Category 1: 3.42<x< = 5.28 ppm years 57 cases
o Category 2: 5.28<x<= 6.51 ppm years 57 cases
o Category 3: x>6.51 ppm years 58 cases
23 of 73 (c) Copyright 2006 E.I. du Pont de Nemours and Company. All Rights Reserved. No portion of this work may be reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001691
FINAL
Exposure lagging 10 years
N = 3,989
o Reference: x <= 3.12 ppm years 54 cases
o Category 1: 3.12<x< = 4.90 ppm years 54 cases
o Category 2: 4.90<x<= 6.40 ppm years 54 cases
o Category 3: x>6.40 ppm years 55 cases
Exposure lagging 15 years
N = 3,986
o Reference: x <= 2.43 ppm years 51 cases
o Category 1: 2.43<x< = 4.19 ppm years 52 cases
o Category 2: 4.19<x<= 5.66 ppm years 52 cases
o Category 3: x>5.66 ppm years 52 cases
Exposure lagging 20 years
N = 3,440
o Reference: x <= 1.66 ppm years 47 cases
o Category 1: 1.66<x< = 3.48 ppm years 47 cases
o Category 2: 3.48<x<= 5.07 ppm years 47 cases
o Category 3: x>5.07 ppm years 48 cases
Exhibit 7B. Cumulative exposure categories for proportional hazards analyses for ischemic heart
disease mortality, stratified by exposure lag period; quartiles determined by cumulative exposure
distribution of entire cohort.
No lag of exposure
N = 4,460
o Reference: x <= 0.99 ppm years 10 cases
o Category 1: 0.99<x< = 4.29 ppm years 61 cases
o Category 2: 4.29<x<= 6.98 ppm years 114 cases
o Category 3: x>6.98 ppm years 50 cases
Exposure lagging 5 years
N = 4,440
o Reference: x <= 1.97 ppm years 26 cases
o Category 1: 1.97<x< = 4.42 ppm years 61 cases
o Category 2: 4.42<x<= 6.24 ppm years 76 cases
o Category 3: x>6.24 ppm years 66 cases
Exposure lagging 10 years
N = 3,989
o Reference: x <= 2.28 ppm years 37 cases
o Category 1: 2.28<x< = 3.85 ppm years 46 cases
o Category 2: 3.85<x<= 5.23 ppm years 37 cases
o Category 3: x>5.23 ppm years 97 cases
Exposure lagging 15 years
24 of 73 (c) Copyright 2006 E.1 du Pont de Nemours and Company. All Rights Reserved. No portion of this work may be reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission ofDuPont.
DEQ-CFW 00001692
FINAL
N = 3,986
o Reference: x <= 1.86 ppm years 38 cases
o Category 1: 1.86<x< = 3.16 ppm years 34 cases
o Category 2: 3.16<x<= 4.27 ppm years 33 cases
o Category 3: x>4.27 ppm years 102 cases
Exposure lagging 20 years
N = 3,440
o Reference: x <= 1.19 ppm years 27 cases
o Category 1: 1.19<x<= 2.38 ppm years 34 cases
o Category 2: 2.38<x<= 3.24 ppm years 28 cases
o Category 3: x>3.24 ppm years 100 cases
Results
Cohort Description
The Washington Works cohort consists of individuals who worked at the plant at any time
between 1948 and 2002. First, 5,476 individuals were originally identified from the
Epidemiology Employee Registry. Of these persons, 22 individuals were excluded for the
following reasons; 1 had no verifiable birth date, and 21 had transferred to the Washington
Works location after December 31, 2002, the end of the mortality surveillance period. This
resulted in 5,454 individuals who were included from the Epidemiology Employee Registry with
an additional 573 individuals included based on work history records obtained from the plant site
Human Resources Department. The resulting cohort for all analyses included 6,027 individuals.
Table 1 shows the descriptive statistics for the historical Washington Works cohort.
Total person -years were 127,513.2 for males, and 18,224.5 for females. Person -years ascribed to
the three cumulative exposure categories were 74,603.6 for Group 1 (lowest potential exposure
to APFO); 52,461.8 for Group 2; and 18,672.3 for Group 3 (highest potential exposure to
APFO).
Mortality Analyses on Entire Cohort
While the DuPont Regional population appears to be the most appropriate reference group for
mortality rate comparisons, we also report SMRs based on both the U.S.A. and West Virginia
rates. The U.S.A. comparisons provide some context for other studies in the published literature,
and the comparisons to the West Virginia state population are presented in response to a request
from study participants. As would be expected, almost all SMRs comparing Washington Works
mortality rates for defined causes to the U.S.A. and West Virginia population mortality rates
were below 100, the standard metric of the SMR indicating no observed differences in the
mortality rates between the compared populations. Further, many SMR estimates were
statistically significantly below this estimate of no effect indicating that Washington Works
employees had lower mortality rates for many causes of death compared to the general
population. Due to concerns about statistical precision, only those causes of death for which
there were at least five deaths observed were considered relevant for consideration of increased
or decreased risk.
25 of 73 (c) Copyright 2006 E.I. du Pont de Nemours and Company. All Rights Reserved. No portion of this work maybe reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001693
Table 2 shows selected SMRs for Washington Works males and females when compared to the
three reference populations. These causes of death were selected based on results from animal
studies, and other occupational studies, and are detailed below. Complete SMR analysis results
are presented in Appendices A-C. There were only 33 deaths among females workers; limiting
the statistical power to detect significant differences in disease -specific mortality rates among
female workers and restricting interpretations of SMRs to all causes of death combined and all
cancers combined.
All Causes of Death
For males, the SMR for all causes of death was 94 (95% Cl: 87-100) based on the Region 1
DuPont population. The SMRs for all causes based on comparisons to West Virginia and total
U.S.A. were 58 (95% CI: 54-62) and 66 (95% CI: 62-71), respectively.
For females, the SMR for all causes of death was 147 (95% CI: 101-207) based on the Region
1 DuPont population. The SMRs for all causes based on comparisons to West Virginia and total
U.S.A. were 73 (95% CI: 51-103) and 81 (95% CI: 56-113), respectively.
All Malignant Neonlasms
For males, the SMR for all malignant neoplasms was 100 (95% CI: 88-114) based on the
Region 1 DuPont population. The SMRs for all malignant neoplasms based on comparisons to
West Virginia and total U.S.A. were 68 (95% CI: 60-78) (WV) and 74 (95% CI: 64-84)
(U.S.A.)
For females, the SMRs for all malignant neoplasms were 149 (95% Cl: 77 260); 79 (95% CI:
41-139), and 87 (95% Cl: 45-151) when comparing against the Region 1 DuPont Population,
West Virginia, and total U.S.A., respectively.
Cancer of Biliary Passages and Liver
Based on seven deaths, the SMRs in males for cancer of biliary passages and liver were 133
(95% CI: 53-274), 104 (95% Cl: 42-215), and 90 (95% Cl: 36-185) when comparing
against the Region 1 DuPont Population, West Virginia, and total U.S.A., respectively.
There was only one death due to cancer of biliary passages and liver among females.
Cancer of Pancreas
For males, the SMRs for cancer of the pancreas were 100 (95% Cl: 50-180), 83 (95% CI:
41-148), and 71 (95% Cl: 36-128) when comparing against the Region 1 DuPont Population,
West Virginia, and total U.S.A., respectively.
There were no reported cases of cancer of the pancreas in females.
26 of 73 (c) Copyright 2006 E.I. du Pont de Netnours and Company. All Rights Reserved. No portion of this work may be reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001694
FINAL
Urinary Tract Cancers
There were 12 deaths from kidney cancer in males; the SMRs were 185 (95% Cl: 95-323), 155
(95% Cl: 80-272), and 156 (95% CI: 80-272) when comparing against the Region 1 DuPont
Population, West Virginia, and total U.S.A., respectively.
No deaths from kidney cancer were seen in females.
There were 7 deaths from cancer of the bladder and other urinary organs in males; the SMRs
were 131 (95% Cl: 53-269), 105 (95% Cl: 42-216), and 101 (95% Cl: 41-209) when
comparing against the Region 1 DuPont Population, West Virginia, and total U.S.A.,
respectively.
One death from bladder cancer was seen in females.
Because there were few deaths from kidney cancer, there was not sufficient statistical power to
fit Cox proportional hazard models for assessing the association of this outcome with exposure
categories. Examination of job histories showed that only half the cases had ever worked in the
APFO-use divisions.
Cancer of Bronchus Trachea, Lung
For males, the SMR for cancer of the bronchus, trachea, and lung was 81 (95% Cl: 63-104)
based on the Region 1 DuPont population The SMRs for cancer of the bronchus, trachea, and
lung based on comparisons to West Virginia and total U.S.A. were 49 (95% Cl: 38-163) (WV)
and 61 (95% Cl: 47-77) (U.S.A.)
Cancer of Prostate
The SMR for cancer of the prostate was 65 (95% Cl: 34-114), and 58 (95% CI: 30-100)),
based on the Region 1 DuPont population and West Virginia, respectively. The SMR for cancer
of the prostate based on comparisons to the total U.S.A. was 52 (95% Cl: 27-91).
Cerebrovascular Disease
For males, the SMR for cerebrovascular disease was 86 (95% Cl: 60-120) based on the Region
I DuPont population. The SMRs for cerebrovascular disease based on comparisons to West
Virginia and total U.S.A. were 60 (95% Cl: 42-84) (WV) and 61 ((95% Cl: 42-85) (U.S.A.).
For females, only one death was due to cerebrovascular disease.
27 of 73 (c) Copyright 2006 E.I. du Pont de Nemours and Company. All Rights Reserved. No portion of this work maybe reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001695
FINAL
All Heart Disease
For males, the SMR for all heart disease was 110 (95% Cl: 98-123) based on the Region 1
DuPont population. The SMRs for all heart disease based on comparisons to West Virginia and
total U.S.A. were 66 (95% Cl: 59-74) (WV) and 80 ((95% CI: 71-89) (U.S.A.).
For females, the SMRs for all heart disease were 143 (95% Cl: 46-333), 51 (95% CI: 17-
119), and 64 (95% Cl: 21-150) when comparing against the Region 1 DuPont Population,
West Virginia, and total U.S.A., respectively.
Ischemic Heart Disease
In males, the SMRs for ischemic heart disease were 109 (95% CI: 96-124), and 69 (95% Cl:
61-78), based on the Region 1 DuPont population and West Virginia, respectively. The SMR
for ischemic heart disease based on comparisons to total U.S.A. was 81 (95% CI: 71-93).
There were only three deaths due to ischemic heart disease in females.
Diabetes Mellitus
Mortality from diabetes mellitus among males was significantly elevated based on comparison to
the DuPont Region 1 population (SMR= 183; 95% CI=112-283), but was below 100.0 in
comparisons to both the West Virginia (SMR= 67; 95% CI=41-104) and U.S.A. population
(SMR= 81; 95% CI=50-125).
There were only two deaths attributed to diabetes among females.
Cox Proportional Hazards Modeling
Ischemic Heart Disease
Table 3 presents the descriptive statistics for the white males used in the proportional hazards
models for IHD, stratified by case/non-case status, and Table 4 shows descriptive statistics for
this subset, stratified by never-APFO-use/ever-APFO-use.
The first CHPM for ischemic heart disease was fit to data for 4,460 white males using the
average intensity as the exposure of interest, with zero lag for exposure. Two models are
presented in Table 5: each includes PFOA exposure variables, and one adjusts for calendar year
of the event and the other adjusts for hire date (pre or post-1954) in the model (1954 was the
median date of hire).
Table 5 also shows the mortality rate ratios by exposure category for the no -lag models using
case calendar -year or the binary variable for hired before 1954 as a potential confounder. When
we looked separately at calendar year of death and date of hire, these two variables were both
statistically significant. For calendar year of death, the MRR is less than one, which means that
the background death rate for ischemic heart disease is going down over the study period. This is
also true for the national mortality rates from ischemic heart disease in the U.S.A. (Figure 7). As
for the date of hire, those hired prior to 1954 had higher risk of death from IHD than those hired
28 of 73 (c) Copyright 2006 E.I. du Pont de Nernours and Company. All Rights Reserved. No portion of this work may be reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001696
FINAL
after 1954. However, when both of these variables (date of hire and calendar year of death) were
accounted for in the model, only calendar year of death remained significant which means that
the effect of the date of hire was confounded by the calendar year of death.
Table 6 presents a summary of the CPHM analyses on IHD conducted for all white males in the
cohort without lagging average intensity exposures, and those with lags of different time
intervals (5, 10, 15, 20 years) to adjust for potential effects of HWSE with the inclusion of both
potential time confounders (case calendar -year and hired before 1954).
These results show no significantly increased MRRs for IHD mortality between exposure
categories for all analyses, with and without lags. Additionally, no trends of increasing MRRs
are seen across exposure categories with the exception of category 4, the highest exposure group.
The increase in MRR with increasing lag provides evidence that analysis using lagged exposures
compensates for the healthy worker survivor effect for this cause of death. Details of these
analyses are presented in Table 6.
Table 7 displays the results from both analyses of cumulative exposure categories for Cox
proportional hazard models of the association between cumulative exposure and IHD mortality.
In the first part of the table (section A), results are reported for categories determined by
quartiles of cumulative exposure among case subjects only. This method ensures that each
exposure category contains one-fourth of the cases (see exhibit 7A) for the corresponding lag
model. Though no estimates of the hazard ratio are statistically significant in any model, the
results from the 10-year lagged exposure model suggest an increasing trend in the mortality rate
ratio for the highest two exposure categories.
Due to the lack of consensus on a universally "best" approach to cumulative exposure
categorization, we performed a second set of analyses using quartiles determined by the entire
WW cohort as a form of sensitivity analysis. Table 7B lists the results of these models
corresponding to cutpoints described in exhibit 7B. Although all estimates were still not
statistically significant, mortality rate ratio estimates for this analysis attenuated towards the null
value of 1.0 for all lagged exposure models including those for the 10-year lag.
Discussion
In this retrospective cohort mortality study, we assessed whether workers at a polymer
production plant exhibited increased mortality from any specific cause of death, as well as the
more general categories of all causes and all malignant diseases. SMRs were generated using
three different reference populations —a regional population from the same company, which
reduced the bias from both the healthy worker effect and regional socio-cultural attributes; the
state population in which the plant was located; and the general U.S.A. population. Although the
site of the study is a manufacturing plant that produces a wide variety of products from many
different chemicals, the only occupational exposure examined was APFO. The areas where this
chemical is used employs about one-third of the site's workers.
Exposure to APFO has been shown to cause benign neoplasms in rodent toxicology studies.
Liver, Leydig-cell, and pancreatic acinar-cell tumors were observed in rats, but all of those
findings are hypothesized to be mediated via PPARa. Humans have low PPARa receptor
expression, and are not as responsive to PPARa agonists [25]. This study had low power to
29 of 73 (c) Copyright 2006 E.I. du Pont de Nemours and Company. All Rights Reserved. No portion of this work maybe reproduced in whole Orin part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001697
FINAL
detect excess risk for these rare tumors, and the increased SMR of 135 for cancer of the biliary
passages and liver, based on seven cases in males, was not statistically significant.
Prostate cancer and cerebrovascular disease, both reported as increased in previous 3M Company
occupational epidemiology reports [1,2], were reduced in this cohort against all reference
populations, cerebrovascular disease significantly so for the U.S.A and West Virginia
populations. The few cases of each of these causes of death did not allow meaningful internal
comparisons.
Despite limited statistical power to evaluate mortality rates for specific cancers, some elevated
relative risks did emerge that bear further scrutiny by worker surveillance and exposure
monitoring. Although animal toxicology data and published occupational studies on workers
exposed to PFOA do not provide any a priori reason to suggest a potential effect on risk for
kidney cancer, comparisons against DuPont Region 1 returned increased, but non -significant
SMRs. However, examination of work histories showed that few cases had spent appreciable
time in the APFO areas.
We did identify an increased mortality risk for diabetes mellitus in this cohort of workers —
driven largely by 20 cases in males and two in females —when comparisons were made to the
regional worker population from the same company (SMR= 183; 95% CI=112-283). However,
comparisons to West Virginia (SMR= 67; 95% CI=41-104) and to the general U.S.A.
population (SMR= 81; 95% CI=50-125) did not indicate an increased risk of mortality due to
diabetes. Although Cox proportional hazard modeling could be done, the small number of cases
would severely limit the value of the estimates.
There is a substantial literature supporting the under -reporting of diabetes, especially of late -
onset or type II diabetes, on death certificates. Differences between countries' mortality
reporting for diabetes has been shown to depend, among other factors, on physician differences
in reporting this disease in Part I of the death certificate or as the underlying cause [26]. In the
U.S.A., a study of the frequency of reporting diabetes on death certificates of 540 known
diabetics showed that diabetes was recorded on just 39 percent of the death certificates and as the
underlying cause of death for only 10 percent of decedents with diabetes. In addition, diabetes
was significantly less likely to be reported on the death certificates of decedents dying of cancer
[27]. Our SMR analyses are based on the underlying cause of death, and it is reasonable to
assume that the prevalence of diabetes in this cohort has been under -ascertained. We know of no
reason why the same under -ascertainment should not apply to the reference populations as well;
thus, any bias in ascertainment would be non -differential. Cardiovascular death rates are higher
in diabetics than in non -diabetics [28-29]. Although cardiovascular disease and late -onset
diabetes share several risk factors (diets high in refined carbohydrates, sedentary lifestyle, age,
and body mass index, for example), a study conducted in Iceland identified an independent effect
of diabetes on coronary heart disease after adjustment for blood pressure, serum lipids, uric acid,
smoking, and height and weight [30]. As discussed below, no increase in cardiovascular disease
was noted for this cohort. Given the number of endpoints examined in the SMR analyses, it is
not surprising to find an isolated increase in one of the causes of death. The lack of agreement
with other studies of PFOA workers, and the lack of any animal toxicology findings to support
this association suggest that the finding is due to chance. However, we will follow up on these
results in future surveillance.
30 of 73 (c) Copyright 2006 E.I. du Pont de Nemoursand Company. All Rights Reserved. No portion of this work may be reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001698
FINAL
Our initial proportional hazards models of ischemic heart disease, an outcome potentially
influenced by increased serum lipids, utilized cumulative exposure. This metric seemed to be the
most biologically appropriate. The results of these models, conducted without lagging of
exposure, showed significantly reduced rate ratios, which were assumed to be due to
confounding by the healthy worker survivor effect (age was controlled for by using it as the time
metric in the Cox model). We then turned to average intensity of exposure. With these analyses,
we introduced the five-year lag of exposure, which appeared to mitigate the effects of the healthy
worker survivor effect, prompting the re -analysis of cumulative exposure with lags. In order to
stabilize the estimates of the mortality rate ratio, the exposure cutpoints were determined first by
dividing the cases into quartiles, as is commonly done in occupational studies.
The multi -dimensionality of occupational exposure metrics contributes to discussion about which
metrics are the more robust, least biased, and most biologically meaningful [31]. In light of this
debate, we have presented analyses using both average intensity and cumulative exposure, with
lagging and without. In addition, we conducted analyses on cumulative exposure with the
cutpoints driven both by case and total cohort distributions of exposure, which provides a
sensitivity analysis for the impact of cut -point selection on the observed exposure -response
relationships.
For ischemic heart disease mortality, no increases in mortality rate ratios were seen in the results
of any analyses conducted using average exposure intensity. Many of the MRRs were below 1.0.
It is well known, however, that for a chronic disease such as IHD, mortality underestimates
morbidity and is therefore not an ideal endpoint for epidemiologic analysis. Furthermore, the rate
ratio for IHD may also be biased by the HWSE, even in internal analyses. The use of lagged
exposures by 5 year periods to adjust for the healthy worker survivor effect did not have much
effect, as estimates of the mortality rate ratio were still less than 1.0. There was, however, an
increased trend in MRRs as the lag time increased from 0 to 20 years by 5-year intervals for
Exposure Category 4 (highest exposure category). While these findings remain statistically non-
significant, the increase in the MRR as the lag increased for the highest exposure group
demonstrated that this approach did indeed compensate for the healthy worker survivor effect
among those who worked long enough to achieve exposures in the highest category.
For proportional hazards models of cumulative exposure, no significant increase in the MRR was
observed with the exception of the 10-year lag model based on the set of exposure categories
with an equal distribution of cases assigned to each exposure group. An elevated relative risk of
1.6 was found in the highest exposure category, and there was an increasing trend in NM with
increasing exposure. While neither MRR estimate for the upper two exposure categories in the
10-year lag model was statistically significant, the apparent trend cannot be ignored.
In order to investigate the sensitivity of the model to the categorization of cumulative exposure,
we redefined cumulative exposure categories based on quartiles of the entire WW cohort.. Effect
estimates from this model were attenuated towards a null value. The highest relative risk was
again seen in the 10-year lagged model where the MRR was 1.3 for the highest exposure
category, but there was no apparent trend. The overall absence of positive effect estimates using
either the 5-, 15-, or 20-year exposure lags suggest that the positive exposure -response trend for
cumulative exposure lagged by 10 years requires further investigation before firm conclusions
can be reached.
31 of 73 (c) Copyright 2006 E.I. du Pont de Nemours and Company. All Rights Reserved. No portion of this work maybe reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001699
FINAL
When we looked separately at calendar year of death and date of hire (before or after 1954 for
IHD), both time variables were statistically significant. For calendar year of death, the MRR was
less than one, which indicates that the background death rate for ischemic heart disease was
going down over the study period. This is also true for the national mortality rates from ischemic
heart disease in the U.S.A. As for the date of hire, those hired prior to 1954 had higher risk of
death from IHD than those hired after 1954. However, when both of these variables (date of hire
and calendar year of death) were accounted for in the model, only calendar year of death
remained significant, evidence that the effect of the date of hire was confounded by the calendar
year of death. This finding underlines the importance of exploring in detail all potential time -
varying confounders in this type of analysis.
Strengths of this study include the availability of biomonitoring data to support retrospective
exposure classification and a large cohort with over fifty years of follow-up. In addition, there
were sufficient mortality data to enable several types of analysis using both external and internal
comparisons, including Cox proportional hazards analysis for ischemic heart disease.
Limitations of this study include the potential loss to follow-up of decedents prior to 1979, a
period where exposures may have been less well -controlled, causing potential bias towards the
null due to the healthy worker survivor effect. Although this loss could have been as high as 10
percent, due to the ascertainment procedures for the DuPont Mortality Registry, it was likely
much smaller due to the establishment of vital status of all cohort members through the Social
Security Administration. Moreover, the lagged exposure approach applied to the ischemic heart
disease analysis was designed to reduce such bias. A major limitation is likely to be the lack of
accounting for confounding by other occupational and non -occupational risk factors. Most
importantly, information was not available for members of the cohort about the major risk
factors for cardiovascular disease (smoking, diet, and other life-style factors). Additionally, no
information was available for cohort members who were being treated with medications such as
statins or anti -hypertensive medications.
Conclusions
The results reported here show no convincing evidence of increased mortality risk associated
with APFO exposure for workers at this plant. These results do show statistically non -significant
elevations in relative risk for kidney cancer and a statistically significant increase in diabetes
mortality for workers at this site. However, given the size and length of follow-up of the study
population, the evidence to thoroughly examine mortality events like kidney cancer or even
diabetes, may not be adequate. Proportional hazards analyses for ischemic heart disease mortality
showed an increase in the model based on equal distribution of cases across cumulative exposure
categories in one lagged analysis (the 10-year lag period). Other exposure lags showed no effect,
and results for a second set of models using a different set of exposure cutpoints were attenuated
toward the null. None of the hazard estimates themselves were statistically significant. Thus the
positive finding in the proportional hazard analysis, as well as the increased diabetes mortality,
might be due to chance. Because of the complexity of the exposure assessment and limited
power for some analyses, additional investigations are needed.
32 of 73 (c) Copyright 2006 E.I. du Pont de Nemours and Company. All Rights Reserved. No portion of this work may be reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission ofDuPont.
DEQ-CFW 00001700
FINAL
References
[1] Gilliland, F.D. and Mandel, J.S. (1993). Mortality among employees of a
perfluorooctanoic acid production plant. J. Occup. Med. 35:950-954.
[2] Alexander, B.H. (2001). Mortality study of workers employed at the 3M Cottage Grove
Facility. Final Report. April 26, 2001. Division of Environmental and Occupational
Health, School of Public Health, University of Minnesota. US EPA AR226-1030018.
[3] Haskell Report. (2006). Ammonium Perfluorooctanoate: Cross -Sectional Surveillance of
Clinical Measures of General Health Status Related to a Serum Biomarker of
Exposure and Retrospective Cohort Mortality Analyses in a Polymer Production Plant. In
review.
[4] Olsen, G.W., Burris, J.M., Burlew, M.M., Mandel, J.H. (2003). Epidemiological
assessment of worker serum perfluorooctanesulfonate (PFOS) and perfluorooctanoate
(PFOA) concentrations and medical surveillance examinations. J. Occup. Environ. Med.
45:260-270.
[5] DuPont Haskell Laboratory (1981). Liver study of Washington Works employees exposed
to C-8: Results of blood biochemistry testing. Unpublished report, HL-673-96.
[6] Gilliland, F.D. and Mandel, J.S. (1996). Serum perfluorooctanoic acid and hepatic
enzymes, lipoproteins, and cholesterol: a study of occupationally exposed men. Am. J. Ind.
Med. 29: 560-568.
[7] Olsen, G.W., Burris, J.M., Burlew, M.M., and Mandel, J.H. (2000). Plasma
cholecystokinin and hepatic enzymes, cholesterol and lipoproteins in ammonium
perfluooctanoate production workers. Drug Chem. Toxicol. 23: 603-620.
[8] Emmett, A.E., Shofer, F.S., Zhang, H., Freeman, D., Desai, C., and Shaw, L.M. (2006a).
Community exposure to perfluorooctanoate: Relationships between serum concentrations
and exposure sources. JOEM 48:759-770.
[9] Emmett, A.E., Zhang, H., Shofer, F.S., Freeman, D., Rodway, N.V., Desai, C., and Shaw,
L.M. (2006b). Community exposure to perfluorooctanoate: Relationships between serum
levels and certain health parameters. JOEM 48: 771-779,
[10] Olsen, G.W., Burris, J.M., Lundberg, J.K., Hansen, K.J., Mandel, J.H., and Zobel, L.R.
(2002a). Identification of fluorochemicals in human sera. 1. American Red Cross adult
blood donors. US EPA Public Docket AR-226.
[11] Olsen, G.W., Burris, J.M., Lundberg, J.K., Hansen, K.J., Mandel, J.H., and Zobel, L.R.
(2002b). Identification of fluorochemicals in human sera. II. Elderly participants in the
adult changes in thought study, Seattle, Washington. US EPA Public Docket AR-226.
33 of 73 (c) Copyright 2006 E.I. du Pont de Nemours and Company. All Rights Reserved. No portion of this work may be reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001701
FINAL
[12] Olsen, G.W., Burris, J.M., Lundberg, J.K., Hansen, K.J., Mandel, J.H., and Zobel, L.R.
(2002c). Identification of fluorochemicals in human sera. III. Pediatric participants in a
group A Streptococci clinical trial investigation. US EPA Public Docket AR-226.
[13] Burris J.M.., Lundberg J.K., Olsen G.W., Simpson D., and Mandel G. (2002).
Determination of serum half-lives of several fluorochemicals. 3M Company. Interim
Report #2. January 11, 2002. US EPA AR 226-1086.
[14] Washburn, S.T., Bingman, T.S., Braithwaite, S.K., Buck R.C., Buxton, W., Clewell, H.J.,
Horoun, L.A., Kester, J.E., Rickard, R.W., and Shipp, A.M. (2005). Exposure assessment
and risk characterization for perfluorooctanoate in selected consumer articles. Environ.
Sci. Technol. 39: 3904-3910.
[15] Kennedy, G.L., Jr., Butenhoff, J.L., Olsen, G.W., O'Connor, J.C., Seacat, A.M., Perkins,
R.G., Biegel, L.B., Murphy, S.R., Farrar, D.G. (2004). The toxicology of
perfluorooctanoate. Crit. Rev. Toxicol. 34:351-384.
[16] Sakr, C.J., Leonard, R.C., Kreckmann, K.H., Slade, M.D., Eisen, E.A., and Cullen, M.R.
(2006). Longitudinal study of serum lipids and liver enzymes in workers with occupational
exposure to ammonium perfluorooctanoate (APFO). Manuscript in review.
[17] Marsh, G.M., Youk, A.O., Stone, R.A., Sefcik, S.S., Alcorn, C.A. (1998). OCMAP-
PLUS: A new occupational cohort mortality analysis program for multifactor work history
and exposure- based analysis. J. Occup. Environ. Med. 40: 351-362.
[18] Gilbert, E. S. (1982). Some confounding factors in the study of mortality and occupational
exposures. Am. J. Epidemiol. 116: 177-188.
[19] Morgan, R. W., Kelsh, M. A., Zhao, K., Heringer, S. (1998). Mortality of aerospace
workers exposed to trichloroethylene. Epidemiology 9: 424-431.
[20] Checkoway, H. and Pearce, N.E. Research Methods in Occupational Epidemiology,
Oxford University Press, New York, 1989.
[21] Gun, R.T., Pratt, N.L., Griffith, E.C., Adams, G.G., Bisby, J.A., and Robinson, K.L.
(2004). Update of a prospective study of mortality and cancer incidence in the Australian
petroleum industry. Occup. And Environ. Med. 61: 150-156.
[22] Arrighi, H.M. and Hertz-Picciotto, I. (1994). The evolving concept of the healthy worker
survivor effect. Epidem. 5: 189-196.
[23] Hertz-Picciotto, I., Arrighi, H.M., Hu, S.-W. (2000). Does arsenic exposure increase the
risk for circulatory disease? Am. J. Epidemiol. 151: 174-181.
[24] Szklo, Moyses, Szklo, M., Nieto, F.J. Epidemiology: Beyond the Basics. Aspen
Publications, 1999.
34 of 73 (c) Copyright 200613.1 du Pont de Nemours and Company. All Rights Reserved. No portion of this work maybe reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001702
FINAL
[25] Klaunig, J.E., Babich, M.A., Baetcke, K.P., Cook, J.C., et al. (2003) PPARa agonist-
induced rodent tumors: Modes of action and human relevance. Crit. Rev in Toxicol.
33:655-780.
[26] Lu, T.H., Walker, S., Johansson, L.A., and Huang, C.N. (2005). An international
comparison study indicated physicians' habits in reporting diabetes in part I of death
certificates affected reported national diabetes mortality. J. Clin. Epidem. 58:1150-1157.
[27] McEwen, L.N., Kim, C., Haan, M., Ghosh, D., Lantz, P.M., Mangione, C.M., Saford,
M.M., Marrero, D., Thompson, J.J., and Herman, W.H. (2006). Diabetes reporting as a
cause of death —Results from the Translating Research Into Action for Diabetes (TRIAD)
study. Diabetes Care 29: 247-253.
[28] Roper, N.A., Bilous, R.W., Kelly, W.F., Unwin, N.C., and Connolly, V.M. (2002). Cause -
specific mortality in a population with diabetes —South Tees Diabetes mortality study.
Diabetes Care 25:43-48.
[29] Fox, C.S., Coady, S., Sorlie, P.D., Levy, D., Meigs, J.B., D'Agostino, R.B., Wilson,
P.W.F., Savage, P.J. (2004). Trends in cardiovascular complications of diabetes.
J.A.M.A. 292:2495-2499.
[30] Vilbergsson, S., Sigurdsson, G., Sigvaldason, H., and Sigfusson, N. (1998). Coronary
heart disease mortality among non -insulin -dependent diabetic subjects in Iceland: the
independent effect of diabetes. The Reykjavik Study 17-year follow-up. J. Internal Med.
244:309-316.
[31] Loomis, D. and Kromhout, H. (2004). Exposure variability: Concepts and applications in
occupational epidemiology. Am. J. Indust. Med. 45:113-122.
35 of 73 (c) Copyright 2006 E.I. du Pont de Nemours and Company. All Rights Reserved. No portion of this work may be reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001703
FINAL
TABLES
36 Of 73 (c) Copyright 2006 E.I. du Pont de Nemours and Company. All Rights Reserved_ No portion of this work may be reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy,. or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001704
FINAL
Table 1
Washington Works mortality study cohort
Washington Works
Mortality Study
Cohort
(as of 12/31/2002)
Males
Females
n
Mean
Min
Max
n
Mean
Min
Max
Cohort
4872
1155
Age at Hire
29
11
70
27
17
56
Year of Hire
1974
1948
2002
1986
1948
2002
Age at Termination
50
19
74
32
18
71
Year of Termination
1989
1955
2004
1993
1967
2004
Duration of Hire (Yrs)
19
0
49
j
10
0
44
Yrs of Follow Up
26
0
55
16
0
55
Age at End of Follow
U
55
20
96
43
21
85
White
95.40%
92.29%
#Active
1650
429
Duration of Hire (Yrs)
17
0
41
14
0
40
Age at End of Follow
Up
46
23
68
44
22
67
#Dead
773
33
#Cancer Deaths
222
12
AgeAtDeath
66
22
96
58
22
85
%White
99.09%
96.97%
37 of 73 (c)Copyright 2006 E.I. du Pont de Nemours and Company. All Rights Reserved. No portion of this work maybe reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001705
FINAL
Table 2
SMRs for selected causes of death in Washington Works males, females compared to
DuPont Region 1 (West Virginia (less Washington Works), Ohio, Virginia, Kentucky, Indiana, Pennsylvania,
Tennessee, and North Carolina), U.S.A. national population, West Virginia state population
MALES
N=4872
Total Mortality: 773
Person Years: 127,513.2
FEMALES
N=1155
Total Mortality: 33
Person Years: 18,224.5
Cause of Death
N
DuPont
Region 1
SMR
U.S.A.
National
SMR
West
Virginia
State
SMR
N
DuPont
Region I
SMR
U.S.A.
National
SMR
West
Virginia
State
SMR
All Causes of Death
(773)
93.6
66.2**
58.1**
(33)
147.2*
80.7
73.4
All Malignant Neo lasms
222)
100.4
73.7**
68.3**
12)
149.0
1 86.6
79.4
Cancer of Biliary Passages
& Liver
(7)
133.1
89.7
104.2
(1)
384.8#
394.5#
551.8#
Cancer of Pancreas
11)
100.5
74.0
82.9
0
0
0
0
Cancer of Bronchus,
Trachea, Lung
(64)
81.3
60.6**
49.0**
(2)
132.9^
69.5A
56.6A
Cancer of Prostate (Males
only)
(12)
65.3
51.8**
57.5
N/A
0
0
0
Cancer of Breast
(0)
0
0
0
2
77.4A
61.1^
63.5A
Cancer of Kidney
(12)
184.7
155.7
155.2
0
NIA
N/A
N/A
Diabetes
(20)
183.1*
81.2
67.0
(2)
796.1^
160.8^
121.7^
Cerebrovascular Disease
(34)
86.1
60.9**
60.1**
(1)
90.5#
48.7#
49.7#
All Heart Disease
(309)
109.9
80.0**
66.3**
(5)
142.7
64.4
51.1
IschZ'c Heart Disease
(236)
109.3
81.4* *
69.0
(3)
135.0
64.0
49.7
(*) SIGNIFICANT AT 5%LEVEL; (**) SIGNIFICANT AT 1%LEVEL; (#) BASED ON 1 CASE; (A) BASED
ON 2 CASES
N/A Not Applicable
38 of 73 (c) Copyright 2006 E.I. du Pont de Nemours and Company. All Rights Reserved. No portion of this work may be reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission ofDuPont.
DEQ-CFW 00001706
FINAL
Table 3
White male workers included in the risk -sets of the proportional hazard analysis for IHD
stratified by case/non-case status
Variable
CASES
NON -CASES
N(%) or Mean (SD)
N(%) or Mean (SD)
[Minimum -Maximum]
[Minimum -Maximum
Total Number
235 (5.27 %)
4225 (94.73 %)
Males
235 (100 %)
4225 (100 %)
White Race (v/s non white)
235 (100 %)
4225 (100 %)
Age at hire
33.72 (9.82)
29.06 (8.77)
[18.21-65.85]
[11.23-70.17]
Year of birth
1921 (11.20)
1945 (15.97)
[1892-1958]
[1890-1973]
Year of hire
1955 (8.92)
1974 (1.5.71)
[1948-1995]
[1948-2002]
Year of death
1987 (11.30)
NA
[1958-2002]
Ever-APFO-use
68 (28.94 %)
2185 (51.720/,)
39 of 73 (c) Copyright 2006 E.I. du Pont de Nemcurs and Company. All Rights Reserved. No portion of this work may be reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001707
FINAL
Table 4
White male workers included in the risk -sets of the proportional hazard analysis stratified
by never-APFO-use/ever-APFO-use status
Variable
NEVER-APFO-USE
EVER-APFO-USE
N(%) or Mean (SD)
N(%) or Mean (SD)
[Minimum -Maximum]
[Minimum -Maximum]
Total Number
2207 (49.48 %)
2253 (50.52 %)
Males
2207 (100 %)
2253 (100%)
White Race
2207 (100 %)
2253 (100%)
(v/s non white)
Age at hire
30.89 (9.42)
27.74 (8.04)
[14.40-70.17]
[11.23-64.15]
Year of birth
1941 (18.37)
1947 (14.10)
[1890-1972]
[1903-1973]
Year of hire
1972 (17.10)
1974 (14.72)
[1948-2002]
[1948-2002]
Average intensity
0.21(0)
0.42 (0.35)
(at end of follow-up)
[0.21-0.21]
[0.21-1.69]
Cumulative exposure
4.06 (2.51)
9.10 (10.00)
(at end of follow-up)
[0.00-9.02]
[0.01-71.85]
Time since hire
18.83 (12.20)
21.00 (12.63)
(at end of follow-up)
[0.00-42.27]
[0.05-48.54]
Cases
167 (7.57 %)
68 (3.02 %)
40 of 73 (c) Copyright 2006 B.I. du Pont de Nemours and Company. All Rights Reserved No portion of this work may be reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001708
FINAL
Table 5
Mortality rate ratios for IHD by exposure category for no -lag analyses using case calendar -
year and year of hire (pre71954) as potential confounders
Hired pre-1954
Case -calendar
NO LAG
year
N = 4,460
NO LAG
N = 4,460
MRR
MRR
( 95 % CI)
95 % CI)
Reference
1
I
Category 1
0.858
0.996
(0.569-1.293)
(0.657-1.509)
Category 2
0.575
0.715
(0.319-1.035)
(0.394-1.298)
Category 3
0.767
0.944
(0.444-1.327)
(0.542-1.645)
Category 4
0.558
0.646
(0.323-0.966)
(0.372-1.123)
Case Calendar-
---
0.965
Year
(0.952-0.978)
Hired before
1.422
1954
(1.075-1.881)
41 of 73 (c) Copyright 2006 E.I. du Pont de Nemours and Company. All Rights Reserved. No portion of this work may he reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001709
FINAL
Table 6
Mortality rate ratios for IHD by average intensity exposure category, including increasing
5-year lags of exposure, using case calendar -year and year of hire (pre-1954) as potential
confounders
NO LAG
5-YEAR LAG
10-YEAR LAG
15-YEAR LAG
20-YEAR LAG
N = 4,460
N = 4,440
N = 3,989
N = 3,986
N = 3,440
MRR
MRR
MRR
MRR
MRR
(95 % Cl)
(95 % Cl)
(95 % CI)
(95 % CI)
(95 % CI)
Reference*
1
1
1
1
1
Category 1
0.996
1.035
1.048
0.976
0.884
(0.657-1.510)
(0.689-1.557)
(0.693-1.582)
(0.643-1.482)
(0.574-1.362)
Category 2
0.715
0.657
0.688
0.763
0.976
(0.394-1.298)
(0.361-1.195)
(0.369-1.284)
(0.409-1.427)
(0.573-1.663)
Category 3
0.944
0.738
0.802
0.943
0.828
(0.541-1.646)
(0.416-1.310)
(0.442-1.457)
(0.519-1.715)
(0.481-1.424)
Category 4
0.646
0.842
0.890
0.975
---
(0.372-1.123)
(0.466-1.521)
(0.491-1.611)
(0.538-1.769)
Case Calendar-
0.965
0.965
0.963
0.963
0.964
Year
(0.951-0.979)
(0.950-0.980)
(0.947-0.979)
(0.946-0.981)
(0.944-0.985)
Hired before
1.001
1.042
1.089
1.087
1.053
1954
(0.738-1.360)
(0.764-1.421)
(0.791-1.501)
(0.780-1.513)
(0.744-1.492)
* Exposure distributions for each category by lag period are listed in exhibit 6.
42 of 73 (c) Copyright 2006 E.I. du Pont de Nemours and Company. All Rights Reserved. No portion of this work may be reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission ofDuPont.
DEQ-CFW 00001710
FINAL
Table 7
Mortality rate ratios for IHD by cumulative exposure category, including increasing 5-year
lags of exposure, using case calendar -year and year of hire (pre-1954) as potential
confounders; A) exposure categories based on case distribution, B) exposure categories
based on cohort distribution.
NO LAG
5-YEAR LAG
10-YEAR LAG
15-YEAR LAG
20-YEAR LAG
A)
N = 4,460
N = 4,440
N = 3,989
N = 3,986
N = 3,440
MRR
MRR
MRR
MRR
MRR
(95 % CI)
(95 % CI)
(95 % CI)
(95 % Cl)
(95 % Cl)
Reference*
1
1
1
1
1
Category 1
1.046
0.864
0.996
0.935
0.647
(0.711-1.539)
(0.579-1.291)
(0.647-1.531)
(0.598-1.461)
(0.407-1.029)
Category 2
1.156
1.204
1.377
1.102
0.692
(0.745-1.793)
(0.757-1.914)
(0.829-2.287)
(0.644-1.887)
(0.388-1.233)
Category 3
1.110
1.077
1.610
1.089
0.764
(0.698-1.767)
(0.657-1.764)
(0.942-2.753)
(0.597-1.984)
(0.393-1.489)
Case Calendar-
0.959
0.958
0.948
0.958
0.969
Year
(0.942-0.977)
(0.940-0.976)
(0.928-0.968)
(0.935-0.982)
(0.943-0.997)
Hired before
0.946
0.952
0.903
1.032
1.096
1954
(0.672-1.333)
(0.671-1.352)
(0.633-1.289)
(0.710-1.501)
(0.733-1.639)
B)
Reference'
1
1
1
1
1
Category 1
1.018
0.980
1.062
0.914
0.967
(0.515-2.010)
(0.607-1.582)
(0.662-1.680)
(0.557-1.502)
(0.568-1.647)
Category 2
1.132
1.014
0.825
0.860
0.931
(0.573-2.235)
(0.603-1.705)
(0.483-1.409)
(0.494-1.497)
(0.505-1.717)
Category 3
1.027
1.019
1.256
1.069
0.882
(0.496-2.127)
(0.571-1.817)
(0.721-2.191)
(0.598-1.910)
(0.461-1.688)
Case Calendar-
0.961
0.961
0.954
0.958
0.967
Year
(0.945-0.978)
(0.943-0.980)
(0.934-0.975)
(0.936-0.981)
(0.940-0.994)
Hired before
0.969
1.008
0.974
1.027
1.095
1954
(0.692-1.357)
(0.711-1.429)
(0.679-1.398)
(0.710-1.484)
(0.742-1.614)
* Exposure distributions for each category by lag period are listed in exhibit 7A.
f Exposure distributions for each category by lag period are listed in exhibit 7B.
43 of 73 (c) Copyright 2006 E.I. du Pont de Nemours and Company. All Rights Reserved No portion of this work may be reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001711
FINAL
FIGURES
44 Of 73 (c) Copyright 2006 E.I. du Pont de Nemours and Company. All Rights Reserved. No portion of this work may be reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001712
FINAL
Figure 1.
Time in Job vs Serum PFOA—Cross-Sectional Study —Job Exposure Category 1
10
0.01
0,001
Job Exposure Category 1
APFO-Use Jobs
Years In Job
10 12
0 JobExpCat1
-3 Years
-8 Years
0.25 ppm
0.75 ppm
45 of 73 (c) Copyright 2006 E.I. du Pont de Nen:ours and Company. All Rights Reserved. No portion of this work may be reproduced in whole or in pan by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001713
FINAL
Figure 2.
Time in Job vs Serum PFOA—Cross-Sectional Study —Job Exposure Category 2
10
0.1
0.01
Job Exposure Category 2
0 2 4 6 8 10 12 14 16 18 20
Years In Job
o JobExpCat2
-3 Years
-8 Years
0.25 ppm
0.75 ppm
46 of 73 (c) Copyright 2006 G.I, du Pont de Nemours and Company. All Rights Reserved. No portion of this work may be reproduced in whole or in pan by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001714
FINAL
10
0.1
Figure 3.
Time in Job vs Serum PFOA—Cross-Sectional Study —Job Exposure Category 3
Job Exposure Category 3
0 2 4 6 8 10 12 14 16 18
Years In Job
o JobExpCat3
�3 Years
-8 Years
0.25 ppm
0.75 ppm
47 of 73 (c) Copyright 2006 E.I. du Pont de Nemours and Company. All Rights Reserved. No portico: of this work may be reproduced in whole or in pan by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001715
FINAL
Figure 4.
Serum PFOA vs Cumulative Exposure - FLAIR Data
Serum PFOA vs Cumulative ExposurePotential
10C
10
0.01
0.001
0.01 0.1 1 10 100
Cumulative Exposure (ppm years)
48 Of 73 (c) Copyright 2006 E.I. du Pont de Nemours and Company. All Rights Reserved. No portion of this work may be reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission ofDuPont.
DEQ-CFW 00001716
FINAL
100
10
0.01
0.001
Figure 5.
Serum PFOA vs Average Intensity of Exposure - FLAIR Data
Serum PFOA vs Average Intensity
0.1 1 10
Average Intensity (ppm)
49 Of 73 (c) Copyright 2006 E.I. du Pont de Nemours and Company. All Rights Reserved. No portion of this work may be reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001717
FINAL
100
10
0.01
0.001
Figure 6.
Serum PFOA vs Concurrent Job Intensity Factor - FLAIR Data
Serum PFOA vs Concurrent Job Intensity factor
0.1 1 10
Concurrent Job Intensity Factor (ppm)
50 of 73 (c) Copyright 2006 E.I. du Pont de Nemours and Company, All Rights Reserved No portion of this work may be reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001718
FINAL
18
16
14
12
10
8
6
4
2
0
Figure 7.
Decreasing IHD mortality rates in the U.S.A.
US rates of death from IHD
1960-64 1965-69 1970-74 1975-79 1980-84 1985-89 1990-94 1995-99 2000-01
5 1 of 73 (c) Copyright 2006 E.I. du Pont de Nemours and Company. All Rights Reserved. No portion of this work may be reproduced in whole or in pan by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
t 20-24
->*- 25-29
30-34
* 35-39
* 40-44
i-45-49
+50-54
--- 55-59
— 60-64
65-69
DEQ-CFW 00001719
FINAL
APPENDICES
52 of 73 (c) Copyright 2006 E.I. du Pont de Nemours and Company. All Rights Reserved. No portion of this work maybe reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001720
FINAL
Appendix A
Washington Works vs Region 1
All -Cause Mortality Surveillance Report: Males
Cause of Death
Observed
Expected
SMR
95%
Lower
95%
U er
99%
Lower
99Ler
U
All Causes of Death
773
826.1
93.6
87.1
100.4
85.1
102.6
Tuberculosis
0
0.4
1 N/A
0.0
866.9
1 0.0
1245.0
All Malignant Neoplasms
222
221.2
100.4
1 87.6
114.5
83.8
119.1
Cancer of Buccal Cavity & Pharynx
4
3.2
123.5
33.6
316.1
20.7
388.7
Cancer of Digestive Organs & Peritoneum
49
52.6
93.2
69.0
123.2
62.5
133.3
Cancer ofEsophagus
4
4.8
83.5
22.8
213.8
14.0
1 262.9
Cancer of Stomach
2
5.7
35.0
4.2
126.3
1.8
1621
Cancer of Large Intestine
1.7
20.9
81.5
47.5
130.4
39.5
147.5
Cancer of Rectum
5
3.7
135.3
43.9
315.6
29.2
382.8
Cancer of Bili Passa es & Liver
7
5.3
133.1
53.5
274.2
38.7
325.7
Cancer of Pancreas
11
10.9
100.5
50.2
179.8
39.5
208.1
Cancer of All Other Digestive Organs
3
1.3
232.8
48.0
680.4
26.2
852.0
Cancer of Respiratory System
70
82.3
85.1
66.3
107.5
61.2
115.0
Cancer of Larynx
3
1.5
195.6
40.4
571.7
22.0
715.8
Cancer of Bronchus, Trachea, Lung
64
78.7
81.3
62.6
103.8
57.5
111.3
Cancer of All Other Respiratory
3
2.0
151.0
3 L2
4412
17.0
552.5
Cancer of Breast
0
0.3
N/A
0.0
1425.3
0.0
2046.9
Cancer of Prostate males only)
12
18.4
65.3
33.8
114.1
26.9
131.5
Cancer of Testes and Other male genital
Organs
1
0.6
169.7
4.2
945.7
0.8
1261.1
Cancer of Kidney
12
6.5
184.7
95.4
322.6
76.1
371.6
Cancer of Bladder and Other Urinary Organs
7
5.4
130.7
52.6
269.4
38.0
320.0
Malignant Melanoma of Skin
2
4.4
45.5
5.5
164.4
2.3
211.0
Cancer of Eye
0
0.4
N/A
0.0
886.7
0.0
1273.5
Cancer of Central Nervous System
9
6.9
130.1
59.5
246.9
45.3
289.0
Cancer of Thyroid & Other Endocrine Glands
3
0.5
633.2
*
130.7
1850.4
71.3
2316.9
Cancer of Bone
2
0.3
648.3
78.4
2342.1
33.4
3006.3
Cancer of All Lymphatic, Haematopoietic
Tissue
29
24.0
120.7
80.8
173.4
70.8
191.4
Non -Hodgkins Lymphoma
9
8.2
109.9
50.3
208.6
38.2
244.2
Hodgkins Disease
2
1.1
179.8
21.8
649.5
9.3
833.7
Leukemia & Aleukemia
12
10.3
116.1
60.0
202.8
47.8
233.6
Cancer of All Other L m ho oietic Tissue
6
4.4
136.7
50.2
297.6
35.0
356.9
All Other Malignant Neoplasms
22 1
15.5
141.9
88.9
214.8
76.0
240.0
53 Of 73 (c) Copyright 2006 E.I. du Pont de Nemours and Company. All Rights Reserved. No portion of this work may be reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001721
FINAL
Appendix A
Washington Works vs Region 1
All -Cause Mortality Surveillance Report: Males (Continued)
Cause of Death
Observed
Expected
SMR
95%
Lower
5%
Tu9pper
99%
Lower
99%
Upper
Benign Neoplasms
1
2.4
42.0
1.0
233.8
0.2
311.7
Diabetes Mellitus
20
10.9
183.1
*
111.8
282.8
94.8
317.4
Cerebrovascular Disease
34
39.5
86.1
59.6
120.3
52.8
132.0
All Heart Disease
309
281.0
109.9
98.0
122.9
94.5
127.1
Rheumatic Heart Disease
5
1.7
302.5
98.2
706.0
65.2
856.2
Ischemic Heart Disease
236
215.9
109.3
95.8
124.2
91.8
129.0
Chronic Endocard. Dis.; Other Myocard.
Insuff.
11
10.3
106.4
53.1
190.3
41.8
220.2
Hypertension with Heart Disease
1
6.2
16.2
*
0.4
90.1
0.1
120.1
All Other Heart Disease
56
46.9
119.4
90.2
155.0
82.3
166.9
Hypertension w/o Heart Disease
5
2.3
214.4
69.6
500.4
46.2
606.8
Non-mali ant Respiratoa Disease
46
50.5
91.1
66.7
121.6
60.2
131.8
Influenza & Pneumonia
14
15.4
90.7
49.6
152.1
40.4
173.8
Bronchitis, Emphysema, Asthma
11
11.2
98.6
49.2
176.5
38.7
204.2
Bronchitis
5
3.7
133.8
43.4
312.1
28.8
378.5
Emphysema
6
6.7
88.9
32.6
193.6
1 22.8
232.1
Asthma
0
0.7
N/A
0.0
551.5
0.0
792.0
Other Non -malignant Respiratory Disease
21
23.9
88.0
54.4
134.4
46.4
150.6
Ulcer of Stomach & Duodenum
0
1.5
N/A
0.0
242.9
0.0
348.8
Cirrhosis of Liver
8
9.2
86.9
37.5
171.2
27.9
201.8
Nephritis & Ne hrosis
8
6.0
132.5
57.2
261.1
42.6
307.8
All External Causes of Death
41
65.2
62.9
**
45.1
85.3 1
40.5
92.9
Accidents
31
40.4
76.7 1
52.1
108.9
45.9
119.9
Motor Vehicle Accidents
20
22.8
87.6
53.5
135.3
45.3
151.9
All Other Accidents
11
17.6
62.6
31.3
112.0
24.6
129.7
Suicides
8
19.1
41.8
**
18.1
82.4
13.4
97.2
Homicides & Other External Causes
2
5.7
35.3
4.3
127.4
1.8
163.5
All Other Causes of Death
78
72.1
108.1
85.5
134.9
79.2
143.8
CERTAIN INFECTIOUS AND PARASITIC
DISEASES
1
1.0
100.1
2.5
557.9
0.5
743.9
Unknown Causes In All Causes Category Only)
0
(*) SIGNIFICANT AT 5% LEVEL; (**)
SIGNIFICANT AT I % LEVEL
54 of 73 (c) Copyright 2006 E.I, du Pont de Nemums and Company. All Rigbts Reserved. No portion of this work maybe reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001722
FINAL
Appendix A
Washington Works vs Region 1
All -Cause Mortality Surveillance Report: Females
Cause of Death
Observed
Expected
SMR
95%
Lower
95%
Upper
99%
Lower
99%
Upper
All Causes of Death
33
22.4
147.2
*
101.3
206.7
89.5
226.9
Tuberculosis
0
0.0
N/A
0.0
491866.7
0.0
706400.0
All Malignant Neoplasms
12
8.1
149.0
77.0
260.3
61.4
299.8
Cancer of Buccal Cavity & Pharynx
0
0.2
N/A
0.0
2064.0
0.0
2964.2
Cancer of Digestive Organs & Peritoneum
2
1.5
130.2
15.8
470.4
6.7
603.8
Cancer of Esophagus
0
0.0
N/A
0.0
14899.0
1 0.0
21397.4
Cancer of Stomach
1
0.0
2586.7
64.7
14412.8
12.9
19218.8
Cancer of Large Intestine
0
0.8
N/A
0.0
440.6
0.0
632.7
Cancer of Rectum
0
0.1
N/A
0.0
4151.5
0.0
5962.2
Cancer of Biliary Passages & Liver
1
0.3
384.8
9.6
2144.2
1.9
2859.2
Cancer of Pancreas
0
0.3
N/A
0.0
1467.2
0.0
2107.1
Cancer of All Other Digestive Organs
0
0.0
N/A
0.0
10537.0
0.0
15132.8
Cancer of Respiratory System
2
1.5
132.2
16.0
477.5
6.8
613.0
Cancer of Larynx
0
0.0
N/A
0.0
43969.0
0.0
63146.6
Cancer of Bronchus, Trachea, Lung
2
1.5
132.9
16.1
1 480.2
6.8
616.4
Cancer of All Other Respiratory
0
0.0
N/A
N/A
Cancer of Breast
2
2.6
77.4
9.4
279.8
4.0
359.1
All Uterine Cancers (Females only)
0
0.0
N/A
0.0
17174.1
0.0
24664.8
Cancer of Cervix Uteri (Females only)
0
0.0
N/A
0.0
20449.0
0.0
29368.1
Cancer of Other Female Genital Organs
0
0.7
N/A
0.0
516.9
0.0
742.3
Cancer of Kidney
0
0.1
N/A
0.0
2793.4
0.0
4011.8
Cancer of Bladder and Other Urinary Organs
0
0.0
N/A 1
0.0
20841.8
0.0
29932.2
Malignant Melanoma of Skin
1
0.0
2138.6
53.5 1
11916.2
10.7
15889.6
Cancer of Eye
0
0.0
N/A
0.0
40988.9 1
0.0
58866.7
Cancer of Central Nervous System
0
0.2
N/A
0.0
1903.6
0.0
2733.9
Cancer of Thyroid & Other Endocrine Glands
0
0.0
NIA
0.0
105702.0
0.0
151805.2
Cancer of Bone
0
0.0
N/A
N/A
Cancer of All Lymphatic, Haematopoietic
Tissue
3
0.8
395.0
81.5
1154.4
44.5
1445.4
Non -Hodgkins Lymphoma
0
0.1
N/A
0.0
2890.2
0.0
4150.7
Hodgkins Disease
0
0.2
N/A
0.0
2072.1
0.0
2975.9
Leukemia & Aleukemia
1
0.3
292.7
7.3
1630.9
1.5
2174.7
Cancer of All Other L m ho oietic Tissue
2
0.1
1783.8
*
215.8
6444.0
91.9
8271.5
All Other Malignant Neoplasms
2
0.3
611.0
73.9
2207.3
31.5
2833.3
55 of 73 (c) Copyright 2006 E.I. du Pont de Nemcurs and Company. All Rights Reserved. No portion of this work maybe reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001723
FINAL
Appendix A
Washington Works vs Region 1
All -Cause Mortality Surveillance Report: Females (continued)
Cause of Death
Observed
Expected
SMR
95%
Lower
95%
Upper
99%
Lower
99%
Upper
Benign Neoplasms
0
0.0
NIA
0.0
18528.4
0.0
26609.7
Diabetes Mellitus
2
0.3
796.1
96.3
2876.1
41.0
3691.7
Cerebrovascular Disease
1
1.1
90.5
2.3
504.4
0.5
672.6
All Heart Disease
5
3.5
142.7
46.3
333.0
30.8
403.8
Rheumatic Heart Disease
0
0.1
N/A
0.0
4456.4
0.0
6400.1
Ischemic Heart Disease
3
2.2
135.0
27.8
394.4
15.2
493.8
Chronic Endocard. Dis.; Other Myocard.
Insuff.
0
0.1
N/A
0.0
3005.8
0.0
4316.8
Hypertension with Heart Disease
0
0.2
N/A
0.0
1724.2
0.0
2476.3
All Other Heart Disease
2
0.9
232.2
28.1
838.7
12.0
1076.5
Hypertension w/o Heart Disease
0
0.1
N/A
0.0
3461.6
0.0
4971.4
Non -malignant Respiratory Disease
3
1.0
294.6
60.8
860.8
33.2
1077.8
Influenza & Pneumonia
0
0.3
N/A
0.0
1292.5
0.0
1856.3
Bronchitis, Emphysema, Asthma
2
0.3
679.9
82.3
2456.1
35.0
3152.6
Bronchitis
1
0.1
756.4
18.9
4214.8
3.8
5620.3
Emphysema
1
0.1
1411.6
35.3
7865.6
7.1
10488.4
Asthma
0
0.1
N/A
0.0
4048.1
0.0
5813.7
Other Non -malignant Respiratory Disease
1
0.4
227.9
5.7
1269.6
1.1
1692.9
Ulcer of Stomach & Duodenum
0
0.0
NIA
0.0
8221.5
0.0
11807.4
Cirrhosis of Liver
1
0.1
804.8
20.1
4484.5
4.0
5979.9
Nephritis & Ne hrosis
0
0.1
N/A
0.0
2671.3
0.0
3836.4
All External Causes of Death
4
3.1
130.8
35.7
335.0
22.0
412.0
Accidents
4
1.6
247.3
67.4
633.3
41.6
778.1
Motor Vehicle Accidents
3
1.4
215.7
44.5
630.4
24.3
789.3
All Other Accidents
1
0.2
441.4
11.0
2459.5
2.2
3279.6
Suicides
0
0.6
NIA
0.0 1
660.3
0.0 1
948.3
Homicides & Other External Causes
0
0.9
N/A
0.0 1
418.6
0.0
601.2
All Other Causes of Death
5
2.2
223.2
72.4
520.7
48.1
631.5
CERTAIN INFECTIOUS AND PARASITIC
DISEASES
0
0.1
N/A
0.0
6277.0
0.0
9014.8
Unknown Causes In All Causes Category Only)
0
(*) SIGNIFICANT AT 5%LEVEL; (**)
SIGNIFICANT AT 1%LEVEL
56 of 73 (c) Copyright 2006 E.1 du Pont de Nemours and Company. All Rights Reserved. No portion of this work may be reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001724
FINAL
Appendix A
Washington Works vs Region 1
All -Cause Mortality Surveillance Report: Totals (Males and Females)
Cause of Death
Observed
Expected
SMR
95%
Lower
95%
Upper
99%
Lower
99%
Upper
All Causes of Death
806
848.5
95.0
88.5
101.8
86.6
104.0
Tuberculosis
0
0.4
N/A
0.0
865A
0.0
1242.8
All Malignant Neoplasms
234
229.2
102.1
89.4
116.0
85.7
120.6
Cancer of Buccal Cavity & Pharynx
4
3.4
117.0
31.9
299.6
19.7
368.4
Cancer of Digestive Organs & Peritoneum
51
54.1
94.3
70.2
123.9
63.7
133.9
Cancer ofEsophagus
4
4.8
83.1
22.6
212.7
14.0
261.5
Cancer of Stomach
3
5.8
52.1
10.7
152.2
5.9
190.6
Cancer of Large Intestine
17
21.7
78.3
45.6
125.4
38.0
141.9
Cancer of Rectum
5
3.8
132.1
42.9
308.2
28.5
373.8
Cancer of Biliary Passages & Liver
8
5.5
144.9
62.6
285.6
46.6
336.6
Cancer of Pancreas
11
11.2
98.2
49.0
175.8
38.6
203.4
Cancer of All Other Digestive Organs
3
1.3
226.7
46.8
662.4
25.5
829.4
Cancer of Respiratory System
72
83.8
85.9
67.2
108.2
62.1
115.6
Cancer of Larynx
3
1.5
194.6
40.1
568.6
21.9
711.9
Cancer of Bronchus, Trachea, Lung
66
80.3
82.2
63.6
104.6
58.5
112.1
Cancer of All Other Respiratory
3
2.0
151.0
31.2
441.2
17.0
552.5
Cancer of Breast
2
2.8
70.4
8.5
254.3
3.6
326.4
All Uterine Cancers (females only)
0
0.0
N/A
0.0
17174.1
0.0
24664.8
Cancer of Cervix Uteri (females only)
0
0.0
N/A
0.0
20449.0
0.0
29368.1
Cancer of Other Female genital Organs
0
0.7
N/A
0.0
516.9
0.0
742.3
Cancer of Prostate males only)
12
18.4
65.3
33.8
114.1
26.9
131.5
Cancer of Testes and Other male genital
Organs
1
0.6
169.7
4.2
945.7
0.8
1261.1
Cancer of Kidney
12
6.6
181.0
93.5
316.2
74.6
364.2
Cancer of Bladder and Other Urinary Organs
7
5.4
130.3
52.4
268.5
37.9
318.9
Malignant Melanoma of Skin
3
4.4
67.5
13.9
197.4
7.6
247.2
Cancer ofEye
0
0.4
N/A
0.0
867.9
0.0
1246.5
Cancer of Central Nervous System
9
7.1
126.5
57.8
240.2
44.0 1
281.1
Cancer of Thyroid & Other Endocrine Glands
3
0.5
628.6
*
129.7
1836.9
70.8
2300.0
Cancer of Bone
2
0.3
648.3
78.4
2342.1
33.4
3006.3
Cancer of All Lymphatic, Haematopoietic
Tissue
32
24.8
129.1
88.3
182.3
77.9
200.4
Non -Hodgkins Lymphoma
9
8.3
108.2
49.5
205.4
37.7
240.5
Hodgkins Disease
2
1.3
155.0
18.8
559.9
8.0
718.7
Leukemia & Aleukemia
13
10.7
121.8
64.8
208.2
52.3
238.8
Cancer of All Other Lym ho oietic Tissue
8
4.5
177.8
76.8
350.3
57.1
412.8
All Other Malignant Neoplasms
24
15.8
151.6
97.1
225.5
83.7
251.0
57 Of 73 (c) Copyright 2006 E.I. du Pont de Nemours and Company. All Rights Reserved. No portion of this work may he reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or othervrise distributed without the express written permission of DuPont.
DEQ-CFW 00001725
FINAL
Appendix A
Washington Works vs Region 1
All -Cause Mortality Surveillance Report: Totals (Males and Females) (continued)
Cause of Death
Observed
Expected
SMR
95%
Lower
95%
Upper
99%
Lower
99%
Upper
Benign Neoplasms
1
2.4
41.6
1.0
231.8
0.2
309.2
Diabetes Mellitus
22
11.2
196.9
**
123.4
298.1
105.5
333.1
Cerebrovascular Disease
35
40.6
86.2
60.1
119.9
53.3
131.4
All Heart Disease
314
284.5
110.4
98.5
123.3
1 94.9
127.5
Rheumatic Heart Disease
5
1.7
289.1
93.5
672.3
62.1
815.3
Ischemic Heart Disease
239
218.2
t 109.5
96.1
124.4
92.1
129.2
Chronic Endocard. Dis.; Other Myocard.
Insuff.
11
10.5
105.1
52.5
188.1
41.3
217.7
Hypertension with Heart Disease
1
6.4
15.6
*
0.4
87.1
0.1
116.1
All Other Heart Disease
58
_ 47.8
121.4
92.2
156.9
84.3
168.8
Hypertension w/o Heart Disease
5
2.4
205.1
66.6
478.5
44.2
580.3
Non -malignant Respiratory Disease
49
51.5
95.2
70.4
125.8
63.8
136.1
Influenza & Pneumonia
14
15.7
89.0
48.7
149.4
39.6
170.6
Bronchitis, Em h sema, Asthma
13
11.4
113.6
60.5
194.2
48.7
222.7
Bronchitis
6
3.9
155.0
56.9
337.4
39.7
404.6
Emphysema
7
6.8
102.7
41.3
211.5
29.9
251.3
Asthma
0
0.8
N/A
0.0
485.4
0.0
1 697.1
Other Non -malignant Respiratory Disease
22
24.3
90.5
56.7
137.0
48.5
153.1
Ulcer of Stomach & Duodenum
0
1.6
N/A
0.0
235.9
0.0
338.8
Cirrhosis of Liver
9
9.3
96.5
44.1
183.1
33.6
214.3
Nephritis & Ne hrosis
8
6.2
129.6
55.9
255.3
41.6
300.9
All External Causes of Death
45
68.2
65.9
**
48.1
88.2
43.4
95.7
Accidents
35
42.0
83.3
58.0
115.9
51.5
126.9
Motor Vehicle Accidents
23
24.2
95.0
60.2
142.5
51.7
158.9
All Other Accidents
12
17.8
67.4
34.9
117.8
27.8
135.7
Suicides
8
19.7
40.7
**
17.6
80.1
13.1
94.4
Homicides & Other External Causes
2
6.6
30.5
3.7
110.3
1.6
141.5
All Other Causes of Death
83
74.4
111.6
88.9
138.3
82.6
147.2
CERTAIN INFECTIOUS AND PARASITIC
DISEASES
1
1.1
94.6
2.4
526.9
0.5
702.6
Unknown Causes (In All Causes Category
Only)
0
(*) SIGNIFICANT AT 5% LEVEL; (**)
SIGNIFICANT AT 1% LEVEL
5 8 Of 73 (c) Copyright 2006 E.I. du Pont de Nemours and Company. All Rights Reserved. No portion of this work may be reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001726
FINAL
Appendix B
Washington Works vs USA
All -Cause Mortality Surveillance Report: Males
Cause of Death
Observed
Expected
SMR
95%
Lower
95%
Upper
99%
Lower
99%
Upper
All Causes of Death
773
1167.0
66.2
**
61.6
71.1
60.3
72.6
Tuberculosis
0
2.0
N/A
0.0
183.7
0.0
263.9
All Malignant Neoplasms
222
301.2
73.7
**
64.3
84.1
61.6
87.5
Cancer of Buccal Cavity & Pharynx
4
7.6
52.9
14.4
135.5
8.9
166.6
Cancer of Digestive Organs & Peritoneum
49
74.1
66.2
**
49.0
87.5
44.4
94.6
Cancer of Esophagus
4
9.6
41.5
11.3
106.4
7.0
130.8
Cancer of Stomach
2
9.8
20.5
**
2.5
74.0
1.1
95.0
Cancer of Large Intestine
17
24.5
69.4
40.4
111.1
33.7
125.7
Cancer of Rectum
5
5.3
94.7
30.7
220.9
20.4
267.9
Cancer of Biliary Passages & Liver
7
7.8
89.7
36.1
184.9
26.1
219.6
Cancer of Pancreas
11
14.9
74.0
36.9
132.3
29.1
153.2
Cancer of All Other Digestive Organs
3
2.2
135.9
28.0
397.2
15.3
497.3
Cancer of Respiratory System
70
110.6
63.3
**
49.3
80.0
45.5
85.5
Cancer of Larynx
3
3.9
76.7
15.8
224.0
8.6
280.5
Cancer of Bronchus, Trachea, Lung
64
105.6
60.6
**
46.7
77.4
42.9
83.0
Cancer of All Other Respiratory
3
1.0
293.1
60.5
856.5
33.0
1072.4
Cancer of Breast
0
0.4
N/A
0.0
952.7
0.0
1368.3
Cancer of Prostate males only)
12
23.2
51.8
*
26.8
90.5
21.3
104.2
Cancer of Testes and other male Genital
Organs
1
1.2
96.9
2.2
484.0
0.4
645.4
Cancer of Kidney
12
7.7
155.7 1
80.4
271.9
64.1
313.2
Cancer of Bladder and Other Urinary Organs
7
6.9
101.4
40.8
208.9
29.5
248.1
Malignant Melanoma of Skin
2
5.1
39.0
4.7
140.7
2.0
180.7
Cancer of Eye
0
0.2
N/A
0.0
2299.0
0.0
3301.8
Cancer of Central Nervous System
9
8.6
105.0
48.0
199.4
36.5
233.3
Cancer of Thyroid & Other Endocrine Glands
3
0.9
332.2
68.5
970.7
37.4
1215.3
Cancer of Bone
2
0.8
251.6
30,4
909.0
13.0
1166.8
Cancer of All Lymphatic, Haematopoictic
Tissue
29
29.6
98.0
65.6
140.7
57.4
155.3
Hodgkins Disease
2
1.9
103.3
12.5
373.0
5.3
478.9
Non -Hodgkins Lymphoma
9
11.3
80.0
36.6
151.9
27.8
177.8
Leukemia & Aleukemia
12
11.1
107.8
55.7
188.3
41
216.9
Cancer of All Other L m ho oietic Tissue
6 1
5.3 1
113.8
41.8
247.8
21.
297.1
All Other Malignant Neoplasms
22 1
24.5 1
89.9
56.3
136.1
48.2
152.1
.59 of 73 (c) Copyright 2006 E.I. du Pont de Nemours and Company. All Rights Reserved. No portion of this work maybe reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001727
FINAL
Appendix B
Washington Works vs USA
All -Cause Mortality Surveillance Report: Males (continued)
Cause of Death
Observed
Expected
SMR
95%
Lower
95%
Upper
99%
Lower
99%
Upper
Benign Neoplasms
1
2.9
35.1
0.9
195.3
0.2
260.5
Diabetes Mellitus
20
24.6
81.2
49.6
125.3
42.0
140.7
Cerebrovascular Disease
34
55.8
60.9
**
42.2
85.1
37.3
93.3
All Heart Disease
309
386.5
80.0
**
71.3
89.4
68.7
92.5
Rheumatic Heart Disease
5
4.0
125.7
40.8
293.4
27.1
355.8
Ischemic Heart Disease
236
289.8
81.4
**
71.4
92.5
68.4
96.1
Chronic Endocard. Dis.; Other Myocard.
Insuff.
11
13.1
83.7
41.8
149.7
32.9
173.2
Hypertension with Heart Disease
1
I L8
8.5
**
0.2
47.3
0.0
63.1
All Other Heart Disease
56
67.8
82.6
62.4
107.3
57.0
115.6
Hypertension w/o Heart Disease
5
4.6
108.3
35.2
252.8
23.4
306.6
Non -malignant spiratory Disease
46
85.4
53.9
**
39.4
71.9
35.6
77.9
Influenza & Pneumonia
14
25.8
54.3
*
29.7
91.1
24.2
104.1
Bronchitis, Emphysema, Asthma
11
23.3
47.2
**
23.6
84.5
18.5
97.7
Bronchitis
5
11.2
44.7
14.5
104.4
9.6
126.6
Emphysema
6
10.3
58.5
21.5
127.3
15.0
152.7
Asthma
0
1.9
N/A
0.0
197.5
0.0
283.7
Other Non -malignant Respiratory
Disease
21
36.3
57.9
**
35.8
88.5
30.5
99.0
Ulcer of Stomach & Duodenum
0
3.5
N/A
0.0
105.7
0.0
151.7
Cirrhosis of Liver
8
29.0
27.6
**
11.9
54.4
8.9
64.1
Nephritis & Nephrosis
8
10.7
74.7
32.3
147.2
24.0 1
173.5
All External Causes of Death
41
124.4
33.0
**
23.7
44.7
21.2
48.7
Accidents
31
73.9
42.0
**
28.5
59,6
25.1
65.6
Motor Vehicle Accidents
20
36.2
55.2
**
33.7
85.2
28.6
95.7
All Other Accidents
11
37.7
29.2
**
14.6
52.3
11.5
60.5
Suicides
8
28.5
28.0
**
12.1
55.2
9.0
65.1
Homicides & Other External Causes
2
22.0
9.1
**
1.1
32.9
0.5
42.2
All Other Causes of Death
78
127.4
61.2
**
48.4
76.4
44.9
81.5
Certain Infectious and Parasitic Diseases
1
14.3
7.0
**
0.2
38.9 1
0.0
51.9
Unknown Causes (In All Causes Category
Only)
0
(*) SIGNIFICANT AT 5% LEVEL; (**)
SIGNIFICANT AT I % LEVEL
60 Of 73 (c) Copyright 2006 E.I. duPom de Nemours and Company. All Rights Reserved No portion of this work maybe reproduced in whole or in part by any electronic,
mechanical or other means,including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission ofDuPont
DEQ-CFW 00001728
FINAL
Appendix B
Washington Works vs USA
All -Cause Mortality Surveillance Report: Females
Cause of Death
Observed
Expected
SMR
95%
Lower
95%
Upper
99%
Lower
99%
Upper
All Causes of Death
33
40.9
80.7
55.5
113.3
49.1
124.4
Tuberculosis
0
0.0
N/A
0.0
8275.0
0.0
11884.3
All Malignant Neoplasms
12
13.8
86.6
44.8
151.4
35.7
174.3
Cancer of Buccal Cavity & Pharynx
0
0.1
N/A
0.0
2486.0
0.0
3570.3
Cancer of Digestive Organs & Peritoneum
2
2.4
84.0
1 10.2
303.4
1 4.3
389.5
Cancer of Esophagus
0
0.1
N/A
0.0
3070.1
0.0
4409.1
Cancer of Stomach
1
0.3
397.1
9.9
2212.9
2.0
2950.8
Cancer of Large Intestine
0
0.9
N/A
0.0
388.6
0.0
558.0
Cancer of Rectum
0
0.2
N/A
0.0
2150.8
0.0
3088.9
Cancer of Biliary Passages & Liver
1
0.3
394.5
1 9.9
2197.9
2.0
2930.9
Cancer of Pancreas
0
0.5
N/A
0.0
698.4
0.0
1003.0
Cancer of All Other Digestive Organs
0
0.1
N/A
0.0
3466.8
0.0
4978.9
Cancer of Respiratory System
2
3.0
67.7
8.2
244.5
3.5
313.9
Cancer of Larynx
0
0.0
N/A
0.0
8045.8
0.0
11555.1
Cancer of Bronchus, Trachea, Lung
2
2.9
69.5
8.4
251.0
3.6
322.2
Cancer of All Other Respiratory
0
0.0
N/A
1
0.0
111919.2
0.0
17117.9
Cancer of Breast
2
3.3
61.1
7.4
220.6
3.1
283.1
All Uterine Cancers Females only)
0
0.9
N/A
0.0
419.5
0.0
602.5
Cancer of Cervix Uteri Females only)
0
0.6
N/A
0.0
636.4
0.0
914.0
Cancer of Other Female Genital Organs
0
0.9
N/A
0.0
416.4
0.0
598.0
Cancer of Kidney
0
0.2
N/A
0.0
1793.7
0.0
2576.0
Cancer of Bladder and Other Urinary
Organs
0
0.1 1
N/A
1
0.0
3722.5
0.0 1
5346.1
Malignant Melanoma of Skin
1
0.2
422.2
10.6
2352.3
2.1
3136.7
Cancer of Eye
0
0.0
N/A
0.0
52400.6
0.0
75255.7
Cancer of Central Nervous System
0
0.4
N/A
0.0
834.8
0.0
1199.0
Cancer of Thyroid & Other Endocrine
Glands
0
0.1
N/A
0.0
6334.1
0.0
9096.8
Cancer of Bone
0
0.0 1
N/A
0.0
8833.8 1
0.0
12686.8
Cancer of All Lymphatic, Haematopoietic
Tissue
3
1.2
245.5
50.6
717.4
27.7
898.2
Hodgkins Disease
0
0.1
N/A
0.0
3891.4
0.0
5588.6
Non -Hodgkins Lymphoma
0
0.5
N/A
0.0
811.3
0.0
1165.2
Leukemia & Aeeukemia
1
0.5
207.0
5.2
1153.4
1.0
1538.0
Cancer of All Other Lymph o oietic Tissue
2
0.2
1051.3
*
127.9
3819.5
54.5
4902.7
All Other Malignant Neoplasms
2
1.0
197.7
23.9
714.1
10.2
916.6
61 of 73 (c) Copyright 2006 E.I. du Pont de Nemours and Company. All Rights Reserved. No portion of this work may be reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001729
FINAL
Appendix B
Washington Works vs USA
All -Cause Mortality Surveillance Report: Females (continued)
Cause of Death
Observed
SMR
95%
Lower
95%
Upper
99%
Lower
99%
Upper
Benign Neoplasms
0
-Expected
0.1
N/A
0.0
2467.4
0.0
3543.6
Diabetes Mellitus
2
1.2
160.8
19.5
580.7
8.3
745.4
Cerebrovascular Disease
I
2.1
48.7
1.2
271.6
0.2
362.2
All Heart Disease
5
7.8
64.4
20.9
150.2
13.9
182.2
Rheumatic Heart Disease
0
0.2
N/A
0.0
1694.6
0.0
2433.7
Ischemic Heart Disease
3
4.7
64.0
13.2
187.1
7.2
234.3
Chronic Endocard. Dis.; Other Myocard.
Insuff.
0
0.4
N/A
0.0
1017.5
0.0
1461.3
Hypertension with Heart Disease
0
0.4
N/A
0.0
852.1
0.0
1223.7
All Other Heart Disease
2
2.1
96.7
113
349.4
5.0
448.5
Hypertension w/o Heart Disease
0
02
N/A
0.0
2038.1
0.0
2927.1
Non -malignant Respiratory Disease
3
2.5
119.6
24.7
349.5
13.5
437.6
Influenza & Pneumonia
0
0.7
N/A
0.0
535.7
0.0
769.4
Bronchitis, Emphysema, Asthma
2
0.9
228.8
27.7
826.4
11.8
1060.8
Bronchitis
1
0.4
236.2
5.9
1315.9
1.2
1754.7
Emphysema
1
0.2
447.2
11.2
2491.9
2.2
3322.9
Asthma
0
0.2
N/A
0.0
1623.5
0.0
2331.6
Other Non -malignant Res iratory Disease
1
0.9
105.7
2.6
589.2
0.5
785.6
Ulcer of Stomach & Duodenum
0
0.1
N/A
0.0
4846.9
0.0
6961.0
Cirrhosis of Liver
1
0.9
105.5
2.6
588.0
0.5
784.1
Nephritis & Ne hrosis
0
0.4
N/A
0.0
915.7
0.0
1315.1
All External Causes of Death
4
5.3
75.5
20.6
193.2
12.7
237.6
Accidents
4
3.1
129.6
35.3
331.7
21.8
407.9
Motor Vehicle Accidents
3
1.9
156A
32.3
457.0
17.6
572.2
All Other Accidents
1
1.2
85.6
2.1
476.7
0.4
635.7
Suicides
0
1.1
N/A
0.0
328.2
0.0
471.3
Homicides & Other External Causes
0
1.1
N/A
0.0
338.6
0.0
486.3
All Other Causes of Death
5
5.8
86.1
27.9
.200.8
18.6
243.6
Certain Infectious and Parasitic Diseases
0
0.7
N/A
0.0
543.5
0.0
780.6
Unknown Causes In All Causes Category On]
0
(*) SIGNIFICANT AT 5% LEVEL; (**)
SIGNIFICANT AT 1 % LEVEL
62 Of 73 (c) Copyright 2006 E.I. du Pont de Nemours and Company. All Rights Reserved. No portion of this work may be reproduced in whole or in pan by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001730
FINAL
Appendix B
Washington Works vs USA
All -Cause Mortality Surveillance Report: Totals (Males and Females)
Cause of Death
Observed
Ex ected
SMR
95%
Lower
95%
Upper
99%
Lower
99%
Upper
All Causes of Death
806
1207.9
66.7
**
62.2
71.5
60.8
73.0
Tuberculosis
0
2.1
N/A
0.0
179.7
0.0
258.1
All Malignant Neoplasms
234
315.0
74.3
**
65.1
84.4
62.4
87.8
Cancer of Buccal Cavity & Pharynx
4
7.7
51.9
14.1
132.9
8.7
163.4
Cancer of Digestive Organs & Peritoneum
51
76.4
66.7
**
49.7
87.7
45.1
94.8
Cancer of Esophagus
4
9.7
41.0
11.2
105.1
6.9
129.2
Cancer of Stomach
3
10.0
30.0
*
6.2
87.6
3.4
109.6
Cancer ofLarge Intestine
17
25.4
66.8
38.9
107.0
32.4
121.0
Cancer of Rectum
5
5.5
91.7
29.8
213.9
19.8
259.5
Cancer of Biliary Passages & Liver
8
8.1
99.3
42.9
195.7
31.9
230.6
Cancer of Pancreas
11
15.4
71.4
35.7
127.8
1 28.1
147.9
Cancer of All Other Digestive Organs
3
2.3
129.7
26.8
378.9
14.6
474.5
Cancer of Respiratory System
72
113.5
63.4
**
49.6
79.9
45.8
95.3
Cancer of Larynx
3
4.0
75.8
15.6
221.4
8.5
277.2
Cancer of Bronchus, Trachea, Lung
66
108.5
60.8
**
47.0
77.4
43.3
82.9
Cancer of All Other Respiratory
3
1.1
284.5
58.7
831.4
32.1
1041.0
Cancer of Breast
2
3.7
54.6
6.6
197.2
2.8
253.2
All Uterine Cancers (Females only)
0
0.9
N/A
0.0
419.5
0.0
602.5
Cancer of Cervix Uteri Females only)
0
0.6
N/A
0.0
636.4
0.0
914.0
Cancer of Other Female Genital Organs
0
0.9
N/A
0.0 1
416.4
0.0
598.0
Cancer of Prostate ales only)
12
23.2
51.8
*
26.8
90.5
21.3
104.2
Cancer of Testes and Other Male Genital
Organs
1
1.2
86.9
2.2
484.0
0.4
645.4
Cancer of Kidney
12
7.9
151.6
78.4
264.9
62.5
305.1
Cancer of Bladder and Other Urinary
Organs
7
7.0
99.9
40.2
205.9
29.1
244.6
Malignant Melanoma of Skin
3
5.4
55.9
11.5
163.2
6.3
204.4
Cancer of Eye
0
0.2
N/A
0.0
2202.4
0.0
3163.0
Cancer of Central Nervous System
9
9.0
99.9
45.7
189.6
34.8
221.9
Cancer of Thyroid & Other Endocrine
Glands
3
1.0
312.0
64.4
911.9
35.2
1141.7
Cancer of Bone
2
0.8
239.1
28.9
863.6
12.3
1108.5
Cancer of All Lymphatic, Haematopoietic
Tissue
32
30.8
103.8
71.0
146.6
62.6
161.1
Hodgkins Disease
2
2.0
98.4
11.9 1
355.6
5.1
456.5
Non -Hod ins Lymphoma
9
11.7
76.9
35.2
146.0
26.8
170.8
Leukemia & Aleukemia
13
11.6
111.9
59.6
191.4
48.0
219.5
Cancer of All Other Lym ho oietic Tissue
8
5.5
146.5
63.3
288.7
47.1
340.3
All Other Malignant Neoplasms
24
25.5
94.2
60.3
140.1
52.0
155.9
63 Of 73 (c) Copyright 2006 E.I. du Pont de Nemours and Company. All Rights Reserved No portion of this work may be reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001731
FINAL
Appendix B
Washington Works vs USA
All -Cause Mortality Surveillance Report: Totals (Males and Females) (continued)
Cause of Death
Observed
Expect d
SMR
95%
Lower
95%
Upper
99%
Lower
99%
Upper
Benign Neoplasms
1
3.0
33.3
0.9
185.6
0.2
247.5
Diabetes Mellitus
22
25.9
85.0
53.3
128.7
45.5
143.8
Cerebrovascular Disease
35
57.9
60.4
**
42.1
84.1
37.4
92.1
All Heart Disease
314
394.2
79.6
**
71.1
89.0
68.5
92.0
Rheumatic Heart Disease
5
4.2
119.2
38.7
278.2
25.7
337.4
Ischemic Heart Disease
239
294.5
81.2
* *
71.2
92.1
68.3
95.7
Chronic Endocard. Dis.; Other Myocard.
Insuff.
11
13.5
81.4
40.6
145.7
32.0
168.6
Hypertension with Heart Disease
1
12.2
8.2
**
0.2
45.6
0.0
60.8
All Other Heart Disease
58
69.8
83.1
63.1
107.4
57.7
115.5
Hypertension w/o Heart Disease
5
4.8
104.2
33.8
243.3
22.5
295.0
Non -malignant Respiratory Disease
49
87.9
55.7
**
41.2
73.7
37.4
79.7
Influenza & Pneumonia
14
26.5
52.9
*
28.9
88.7
23.5
101.4
Bronchitis, Emphysema, Asthma
13
24.2
53.8
*
28.6
91.9
23.1
105.4
Bronchitis
6
11.6
51.7
19.0
112.5
13.2
135.0
Emphysema
7
10.5
66.8
26.8
137.6
19.4
163.5
Asthma
0
2.1
N/A
0.0
176.1
0.0
252.9
Other Non -malignant Respiratory Disease
22
37.2
59.1
**
37.0
89.4
31.7
99.9
Ulcer of Stomach & Duodenum
0
3.6
N/A
0.0
103.4
0.0
148.5
Cirrhosis of Liver
9
29.9
30.1
**
13.8
57.1
10.5
66.9
Nephritis & Ne hrosis
8
11.1
72.0
31.1
141.9
23.1
167.2
All External Causes of Death
45
129.7
34.7
**
25.3
46.4
22.8
50.4
Accidents
35
77.0
45.5
**
31.7
63.2
28.1
69.3
Motor Vehicle Accidents
23
38.2
60.3
*
38.2
90.5
32.8
100.9
All Other Accidents
12
38.8
30.9
**
16.0
54.0
12.7
62.2
Suicides
8
29.7
27.0
**
11.6
53.2
8.7
62.6
Homicides & Other External Causes
2
23.1
8.7
**
1.0
31.3
0.4
40.2
All Other Causes of Death
83
133.2
62.3
**
49.6
77.3
46.1
82.2
Certain Infectious and Parasitic Diseases
1
15.0
6.7
**
0.2 1
37.2
0.0
49.6
Unknown Causes (In All Causes Category
Only)
0
(*) SIGNIFICANT AT 5% LEVEL; (**)
SIGNIFICANT AT 1% LEVEL
64 Of 73 (c) Copyright 2006 E.I. du Pont de Nemours and Company. All Rights Reserved. No portion of this work maybe reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001732
FINAL
Appendix C
Washington Works vs West Virginia
All -Cause Mortality Surveillance Report: Males
Cause of Death
Observed
Expect d
SMR
95%
Lower
95%
Upper
99%
Lower
99%
Upper
All Causes of Death
773
1331.3
58.1
**
54.0
62.3
52.8
63.7
Tuberculosis
0
2.1
N/A
0.0
176.8
0.0
253.9
All Malignant Neoplasms
222
325.2
1 68.3
**
59.6
77.9
57.0
81.0
Cancer of Buccal Cavity & Pharynx
4
6.4
62.1
16.9
159.0
10.4
195.5
Cancer of Digestive Organs & Peritoneum
49
68.6
71.5
*
52.9
94.5
47.9
102.2
Cancer of Esophagus
4
8.4
47.4
12.9
121.4
8.0
149.2
Cancer of Stomach
2
8.1
24.5
*
3.0
88.7
1.3
113.8
Cancer of Large Intestine
17
23.9
71.1
41.4
113.8
34.5
128.7
Cancer of Rectum
5
5.8
86.3
28.0
201.4
18.6
244.2
Cancer of Biliary Passages & Liver
7
6.7
104.2
41.9
214.6
30.3
254.9
Cancer of Pancreas
11
13.3
92.9
41.4
149.3
32.6
171.6
Cancer of All Other Digestive Organs
3
2.3
131.8
27.2
385.2
14.9
482.3
Cancer of Respiratory System
70
136.1
51.4
**
40.1
65.0
37.0
69.5
Cancer of Larynx
3
4.5
67.2
13.9
196.3
7.6
245.8
Cancer of Bronchus, Trachea, Lupy2
64
130.7
49.0
**
37.7
62.5
34.6
67.0
Cancer of All Other Respiratory
3
0.9
319.1
65.8
932.6
36.0
1167.7
Cancer of Breast
0
0.4
N/A
0.0
987.4
0.0
1418.0
Cancer of Prostate (Males only)
12
20.9
57.5
29.7
100.4
23.7
115.6
Cancer of Testes and Other Male Genital
Organs
1
1.3
75.7
1.9
421.9
0.4
562.6
Cancer of Kidney
12
7.7
155.2
80.2
271.2
63.9
312.4
Cancer of Bladder and Other Urinary
Organs
7
6.7
104.7
42.1
215.6
30.5
2562
Malignant Melanoma of Skin
2
5.5
36.4
4.4
131.4
1.9
168.7
Cancer of Eye
0
0.2
N/A
0.0
2230.9
0.0
3203.9
Cancer of Central Nervous System
9
8.0
112.0
51.2
212.5
39.0
248.8
Cancer of Thyroid & Other Endocrine
Glands
3
1.0
301.1
62.1
880.0
33.9
1101.9
Cancer of Bone
2
0.9
230.9
27.9
833.9
11.9
1070.5
Cancer of All Lymphatic, Haematopoietic
Tissue
29
30.3
95.8
64.2
137.6
56.2
151.9
Hod ins Disease
2
1.9
107.6
13.0
388.6
5.5 J
498.8
Non -Hodgkins Lymphoma
9
11.2
80.7
36.9
153.2
28.1
179.3
Leukemia & Aleukemia
12
12.0
100.2
51.8
175.1
41.3
201.6
Cancer of All Other Lym ho oietic Tissue 1
6
5.3
114.1
41.9
248.3
29.2
297.8
All Other Malignant Neoplasms
22
31.2
70.5
44.2
106.7
37.8
119.2
65 Of 73 (c) Copyright 2006 E.I. du Pont de Nemours and Company. All Rights Reserved. No portion of this work may be reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission ofDuPont.
DEQ-CFW 00001733
FINAL
Appendix C
Washington Works vs West Virginia
All -Cause Mortality Surveillance Report: Males (continued)
Cause of Death
Observed
Expected
SMR
95%
Lower
95%
Upper
99%
Lower
99%
Upper
Benign Neoplasms
1
3.5
28.3
0.7
157.5
0.1
210.1
Diabetes Mellitus
20
29.8
67.0
41.0
103.5
34.7
116.2
Cerebrovascular Disease
34
56.6
60.1
**
41.6
83.9
36.9
92.1
All Heart Disease
309
465.8
66.3
**
59.1
74.2
57.0
76.7
Rheumatic Heart Disease
5
4.3
115.7
37.5
269.9
24.9
327.4
Ischemic Heart Disease
236
342.1
69.0
**
60.5
78.4
58.0
91.4
Chronic Endocard. Dis.; Other Myocard.
Insuff.
11
15.7
70.1
35.0
125.5
27.6
145.2
Hypertension with Heart Disease
1
9.7
10.3
* *
0.3
57.5
0.1
76.7
All Other Heart Disease
56
94.0
59.6
* *
45.0
77.3
41.1
83.3
Hypertension w/o Heart Disease
5
4.2
117.8
38.2
274.8
25A
333.3
Non -malignant Respiratory Disease
46
116.3
39.6
* *
29.0
52.8
26.2
57.2
Influenza & Pneumonia
14
27.5
51.0
**
27.9
85.5
22.7
97.7
Bronchitis, Emphysema, Asthma
11
29.5
37.3
**
18.6
66.7
14.6
77.1
Bronchitis
5
16.8
29.8
**
9.7
69.5
6.4
84.3
Emphysema
6
11.1
54.1
19.9
117.8
13.9
141.2
Asthma
0
1.6
N/A
0.0
224.3
0.0
322.1
Other Non -malignant Respiratory Disease
21
59.2
35.4
**
21.9
54.2
18.7
60.7
Ulcer of Stomach & Duodenum
0
3.5
N/A
0.0
106.0
0.0
152.3
Cirrhosis of Liver
8
27.5
29.1
**
12,6
57.4
9.4
67.6
Nephritis & Ne hrosis
8
13.5
59.2
25.6
116.7
19.0
137.5
All External Causes of Death
41
146.0
28.1
**
20.2
38.1
18.1
41.5
Accidents
31
94.6
32.8
**
22.3
46.5
19.6
51.2
Motor Vehicle Accidents
20
45.4
44.0
**
26.9
68.0
22.8
76.3
All Other Accidents
11
49.1
22.4
**
11.2
40.1
8.8
46.4
Suicides
8
33.1
24.2
**
10.4
47.6
7.8
56.1
Homicides & Other External Causes
2
18.3
10.9
* *
1.3
39.4
0.6
50.6
All Other Causes of Death
78
138.1
56.5
**
44.6
70.5
41.4
75.1
Certain Infectious and Parasitic Diseases
1
3.2
30.9
0.8
172.1
0.2
229.5
Unknown Causes (In All Causes Category
Only)
0
(*) SIGNIFICANT AT 5% LEVEL; (**)
SIGNIFICANT AT 1% LEVEL
J_
-
66 of 73 (c) Copyright 2006 E.1 du Pont de Nemours and Company. All Rights Reserved. No portion of this work may be reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001734
FINAL
Appendix C
Washington Works vs West Virginia
All -Cause Mortality Surveillance Report: Females
Cause of Death
Observed
Expect d
SMR
95%
Lower
95%
Upper
99%
Lower
99%
Upper
All Causes of Death
33
45.0
73.4
50.5
103.1
44.7
113.2
Tuberculosis
0
0.0
N/A
0.0
9008.5
0.0
12937.7
All Malignant Neolasms
12
15.1
79.4
41.0
138.7
32.7
159.8
Cancer of Buccal Cavity & Pharynx
0
0.1
N/A
0.0
3027.2
0.0
4347.6
Cancer of Digestive Organs & Peritoneum
2
2.3
87.0
1 10.5
314.1
4.5
403.2
Cancer ofEsophagus
0
0.1
N/A
0.0
4248.5
0.0
6101.6
Cancer of Stomach
1
0.2
551.8
13.8
3074.9
2.8
4100.2
Cancer of Large Intestine
0
1.0
N/A
0.0
356.1
0.0
511.4
Cancer of Rectum
0
0.2
N/A
0.0
1992.8
0.0
2861.9
Cancer of Biliary Passages & Liver
1
0.2
441.4
11.0
2459.7
2.2
3279.9
Cancer of Pancreas
0
0.5
N/A
0.0
778.4
0.0
1 1117.9
Cancer of All Other Digestive Orgam
0
0.1
NIA
0..0
3346.9
0.0
4806.9
Cancer of Respiratory System-
2
3.6
55.2
6.7
199.3
2.8
255.8
Cancer of Larynx
0
0.1
N/A
0.0
5906.2
0.0
8482.2
Cancer of Bronchus, Trachea, Lung
2
3.5
56.6
6.8
204.3
2.9
262.3
Cancer of All Other Respiratory
0
0.0
N/A
0.0
13298.5
0.0
19098.8
Cancer of Breast
2
3.1
63.5
7.7
229.5
3.3
294.6
All Uterine Cancers Females only)
0
1.2
N/A
0.0
319.3
0.0
458.6
Cancer of Cervix Uteri (Females only)
0
0.8
N/A
0.0
442.8
0.0
635.9
Cancer of Other Female Genital Organs
0
0.9
N/A
0.0
397.2
0.0
570.4
Cancer of Kidney
0
0.2
NIA
0.0
1690.2
0.0
2427.4
Cancer of Bladder and Other Urinary
Organs
0
0.1
N/A
0.0
2837.0
0.0
4074.4
Malignant Melanoma of Skin
1
0.3
338.9
8.5
1888.5
1.7
2518.2
Cancer ofEye
0
0.0
N/A
0.0
48475.7
0.0
69618.9
Cancer of Central Nervous System
0
0.5
N/A
0.0
764.4
0.0
1097.9
Cancer of Thyroid & Other Endocrine
Glands
0
0.1
N/A
0.0
6825.2
0.0
9802.0
Cancer of Bone
0
0.0
N/A
0.0
7639.3
0.0
10971.2
Cancer of All Lymphatic, Haematopoietic
Tissue
3
1.3
235.1
48.5
687.2
26.5
860.4
Hodgkins Disease
0
0.1
N/A
0.0
3287.9
0.0
4721.9
Non -Hodgkins Lymphoma..
0
0.5
N/A
0.0
804.2
0.0
1155.0
Leukemia & Aleukemia
1
0.5
187.6
4.7
1045.3
0.9
1393.8
Cancer of All Other L m ho oietic Tissue
2
0.2
1165.6
*
141.0
4210.9
60.0
5405.1
All Other Malignant Neoplasms
2
1.3
151.5
18.3
547.4
7.8
702.6
67 of 73 (c) Copyright 2006 E.I. du Pont de Nemours and Company. All Rights Reserved. No portion of this work may be reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001735
FINAL
Appendix C
Washington Works vs West Virginia
All -Cause Mortality Surveillance Report: Females (continued)
Cause of Death
Observed
Expected
SMR
95%
Lower
95%
Upper
99%
Lower
99%
Upper
Benign Neoplasms
0
0.2
NIA
0.0
2200.4
0.0
3160.2
Diabetes Mellitus
2
1.6
121.7
14.7
439.6
6.3
564.2
Cerebrovascular Disease
1
2.0
49.7
1.2
277.2
0.2
369.6
All Heart Disease
5
9.8
51A
16.6
119.3
11.0
144.6
Rheumatic Heart Disease
0
0.3
NIA
0.0
1272.7
0.0
1827.8
Ischemic Heart Disease
3
6.0
49.7
10.3
145.3
5.6
182.0
Chronic Endocard. Dis.; Other Myocard.
Insuff.
0
0.5
N/A
0.0
792.8
0.0
1138.5
Hypertension with Heart Disease
0
0.3
N/A
0.0
1239.2
0.0
1779.7
All Other Heart Disease
2
2.7
74.1
9.0
267.7
3.8
1 343.6
Hypertension w/o Heart Disease
0
0.2
N/A
0.0
1940.3
0.0
2786.5
Non -malignant Respiratory Disease
3
3.1
95.7
19.7
279.7
10.8
350.2
Influenza & Pneumonia
0
0.7
NIA
0.0
526.5
0.0
756.2
Bronchitis, Emphysema, Asthma
2
1.2
173.9
21.0
628.2
9.0
806.3
Bronchitis
1
0.7
146.8
3.7
817.7
0.7
1090.4
Emphysema
1
0.3
383.1
9.6
2134.5
1.9
2846.2
Asthma
0
0.2
N/A
0.0
1776.0
0.0
2550.7
Other Non -malignant Respiratory Disease
1
1.3
77.9
1.9
434.0
0.4
578.7
Ulcer of Stomach & Duodenum
0
0.1
N/A
0.0
5737.2
0.0
8239.5
Cirrhosis of Liver
1
0.7
150.1
1
3.8 1
836.6
0.8
1115.5
Nephritis & Ne hrosis
0
0.5
N/A
0.0
806.0
0.0
1157.5
All External Causes of Death
4
5.8
69.4
18.9
177.8
11.7
218.6
Accidents
4
3.6
109.9
30.0
281.5
18.5
346.1
Motor Vehicle Accidents
3
2.5
118.0
24.3
344.7
13.3
431.7
All Other Accidents
1
1.1
91.3
2.3
508.6
0.5
678.1
Suicides
0
1.1
N/A
0.0
340.4
0.0
488.9
Homicides & Other External Causes
0
1.0
NIA
0.0
355.2
0.0
510.1
All Other Causes of Death
5
5.9
85.0
1
27.6 1
198.5
18.3 1
240.7
CERTAIN INFECTIOUS AND PARASITIC
DISEASES
0
0.1
N/A-
0.0
2506.3
0.0
3599A
Unknown Causes In All Causes Category Only)
0
(*) SIGNIFICANT AT 5% LEVEL; (**)
SIGNIFICANT AT 1 % LEVEL
68 of 73 (c) Copyright 2006 E.I. du Pont de Nemours and Company. All Rights Reserved. No portion of this work maybe reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001736
FINAL
Appendix C
Washington Works vs West Virginia
All -Cause Mortality Surveillance Report: Totals (Males and Females)
Cause of Death
Observed
Expected
SMR
95%
Lower
95%
-Upper
99%
Lower
99%
Upper
All Causes of Death
806
1376.3
58.6
**
54.6
62.8
53.4
64.1
Tuberculosis
0
2.1
N/A
0.0
173.4
0.0
249.0
All Malignant Neoplasms
234
340.3
1 68.8
**
60.2
78.2
57.7
81.2
Cancer of Buccal Cavity & Pharynx
4
6.6
60.9
16.6
156.0
10.2
191.8
Cancer of Digestive Organs &
Peritoneum
51
70.9
72.0
*
53.6
94.6
48.7
102.2
Cancer of Esophagus
4
8.5
46.9
12.8
120.1
7.9
147.7
Cancer of Stomach
3
8.3
36.0
7.4
105.3
4.1
131.8
Cancer of Large Intestine
17
25.0
68.1
39.7
109.1
33.1
123.4
Cancer of Rectum
5
6.0
83.6
27.1
195.1
18.0
236.7
Cancer of Biliary Passages & Liver
8
6.9
115.2
49.7
226.9
37.0
267.4
Cancer of Pancreas
11
13.7
80.0
39.9
143.2
31.4
165.7
Cancer of All Other Digestive Organs
3
2.4
125.7
25.9
367.4
14.2
460.0
Cancer of Respiratory System
72
139.7
51.5
**
40.3
64.9
37.2
69.3
Cancer of Larynx
3
4.5
66.2
13.7
193.6
7.5
242.4
Cancer of Bronchus, Trachea, Lung
66
134.2
49.2
**
38.0
62.5
35.0
67.0
Cancer of All Other Respiratory
3
1.0
310.0
64.0
905.9
34.9
1134.2
Cancer of Breast
2
3.5
56.8
6.9
205.1
2.9
263.3
All Uterine Cancers (Females only)
0
1.2
N/A
0.0
319.3
0.0
458.6
Cancer of Cervix Uteri Females only)
0
0.8
N/A
0.0
442.8
0.0
635.9
Cancer of Other Female Genital Organs
0
0.9
N/A
0.0
397.2
0.0
570.4
Cancer of Prostate Males only)
12
20.9
57.5
29.7
100.4
23.7
115.6
Cancer of Testes and Other Male Genital
Organs
1
1.3
75.7
1.9
421.9
0.4
562.6
Cancer of Kidney
12
7.9
151.0
78.0
263.7
62.2
303.8
Cancer of Bladder and Other Urinary
Organs
7
6.8
102.7
41.3
211.5
29.9
251.3
Malignant Melanoma of Skin
3
5.8
51.8
10.7
151.4
5.8
189.5
Cancer of Eye
0
0.2
N/A
0.0
2132.7
0.0
3063.0
Cancer of Central Nervous System
9
8.5
105.6
48.3
200.5
36.8
234.7
Cancer of Thyroid & Other Endocrine
Glands
3
1.1
285.6
58.9
834.7
32.2
1045.2
Cancer of Bone
2
0.9
218.7
26.5
789.9
11.3
10139
Cancer of All Lymphatic,
Haemato oietic Tissue
32
31.5
101.5
69.4
143.3
61.2
157.5
Hodgkins Disease
2
2.0
101.4
12.3
366.5
5.2
470.4
Non -Hodgkins Lymphoma
9
11.6
77.5
35.4
147.1
27.0
172.2
Leukemia & Aleukemia
13
12.5
103.9
55.3
177.7
44.6
203.9
Cancer of All Other Lymphopoietic
Tissue
8
SA
147.3
63.6
290.3
47.3
342.1
All Other Malignant Neoplasms
24
32.5
73.8
47.3
109.8
40.7
122.2
69 of 73 (c) Copyright 2006 E.I. du Pont de Nernours and Company. All Rigbts Reserved. No portion of this work maybe reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001737
FINAL
Appendix C
Washington Works vs West Virginia
All -Cause Mortality Surveillance Report: Totals (Males and Females) (continued)
Cause of Death
Observed
Expect d
SMR
95%
Lower
95%
Upper
99%
Lower
99%
Upper
Benign Neoplasms
1
3.7
27.0
0.7
150.4
0.1
200.6
Diabetes Mellitus
22
31.5
69.9
43.8
105.8
37.5
118.2
Cerebrovascular Disease
35
58.6
59.7
**
41.6
83.1
36.9
91.0
All Heart Disease
314
475.6
66.0
1**
58.9
1 73.7
56.8
76.3
Rheumatic Heart Disease
5
4.6
108.4
35.2
253.0
23.4
306.8
Ischemic Heart Disease
239
348.1
68.7
**
60.2
77.9
57.7
81.0
Chronic Endocard. Dis.; Other Myocard.
Insuff.
11
16.1
68.1
34.0
121.9
26.8
141.1
Hypertension with Heart Disease
1
10.0
10.0
**
0.3
55.8
0.1
74.4
All Other Heart Disease
58
96.7
60.0
**
45.5
77.5
41.6
83.4
Hypertension w/o Heart Disease
5
4.4
112.7
36.6
263.0
24.3
319.0
Non -malignant Resirato Disease
49
119.4
41.0
1**
30.4
54.3
27.5
58.7
Influenza & Pneumonia
14
28.2
49.7
**
27.2
83.4
22.1
95.2
Bronchitis, Emphysema, Asthma
13
303
42.4
**
22.6
72.5
18.2
83.1
Bronchitis
6
17.5
34.3
**
12.6
74.7
8.8
89.6
Emphysema
7
11.4
61.7
24.8
127.1
17.9
150.9
Asthma
0
1.9
NIA
0.0
199.1
0.0
286.0
Other Non -malignant Respiratory Disease
22
60.5
363
**
22.8
55.0
19.5
61.5
Ulcer of Stomach & Duodenum
0
3.5
N/A
0.0
104.1
0.0
149.5
Cirrhosis of Liver
9
28.1
32.0
**
14.6
60.7
11.1
71.1
Nephritis & Ne hrosis
8
14.0
57.3
24.7
112.8
18.4
133.0
All External Causes of Death
45
151.8
29.7
**
21.6
39.7
19.5
43.1
Accidents
35
98.2
35.6
**
24.8
49.6
22.0
54.3
Motor Vehicle Accidents
23
48.0
47.9
**
30.4
71.9
26.1
80.2
All Other Accidents
12
50.2
23.9
**
12.3
41.7
9.8
48.1
Suicides
8
34.2
23.4
**
10.1
46.1
7.5
54.3
Homicides & Other External Causes
2
19.4
10.3
**
1.2
37.3
0.5
47.9
All Other Causes of Death
83
144.0
57.6
**
45.9
71.5
42.6
76.0
CERTAIN INFECTIOUS AND PARASITIC
DISEASES
1
3.4
29.5
0.7
164.6
0.1
219.5
Unknown Causes (In All Causes Category
Only)
0
(*) SIGNIFICANT AT 5% LEVEL; (**)
SIGNIFICANT AT I % LEVEL
70 of 73 (c) Copyright 2006 E.I. du Pont de Nemours and Company. All Rights Reserved. No portion of this work may be reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001738
FINAL
Appendix D
Job Exposure Category Development based on Division and Job
71 of 73 (c) Copyright 2006 E.I. du Pont de Nemours and Company. All Rights Reserved. No portion of this work may be reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001739
FINAL
72 Of 73 (c) Copyright 2006 E.I. du Pont de Nemours and Company. All Rights Reserved. No portion of this work maybe reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001740
FINAL
TEFLON@ COPOLYMERS I 7 E
PROD._ _ -v SRTECHASSOC 0.292 0.197 } 0387 2 _ _ _ 2 _ 2
RESEARCH i AREA SUPT TECH _ 0.296 0.296_ 0.296 i _ I V _ ., f 1_ 2
TEFLON@ COPOLYMERS
PROD SUPERVISOR 0307 ' 0123 239 E 6 2� 3 11 2
.�,.._.._..._., _ _..._ ! �.
RESEARCH SENIOR TECHNICIAN 0.31 0.31 i 0.31 1 1 _ I 2
TEFLON@ COPOLYMERS
PROD. DIVISION DMSION ENGINEER 033 i 0.33033 _ 1 3 1_ 2
TEFLON@ PROD. ENVIR CONT CONSULT_ 0.34 j 0,329 0.35 2� ! _ 2 2
... _._ ... -. . _
RESEARCH SR TECH ASSOC 0.344 ! 0.058 0.559 E 2 _ 3 3 t _ -': 8 2
TEFLON@ COPOLYMERS
PROD _6810 OPERATOR I 4. 0.349 ! 0.349 ! 0.31 , 1 ! _ _ _ 1 2
TEFLON MAINTENANCE 6720 STC/SPS MECH - 0.35 0 159 0 54 j - I 1 _ 2 2
i _
l TEFLON@ POLYMERS PROD SR CHEMIST 0,356 0.308 ' 0.405 2 7 1 2 2
i f
! TEFLON_@_POLYMERS PROD MAINT SUPT 0.363 0.363 0.363 _ _ _ 1 _ 1_ 2
} TEFLON@ COPOLYMERS
PROD. SR ENGINEER 0.363 0.101 1 1 4 1 _ _ 5 2
TECHNICAL TECH ASSOC 0.369 0.149 i 0.589 1 1 1 2� 2
E
TEFLON@ COPOLYMERS
PROD. 4420 LABORATORIAN 0.382 } 0.166 p 0 708 ¢ 7 2y 9 _ _ 2
EFLON@ POLYMERS PROD AREA SUPT 0.39 0.112 0 837 3 2 5 _ 2
TEFLON@ COPOLYMERS E E
PROD. PROCESS ENGINEER 0.427 0.29 0.574 E I 1 2 2
TEFLON� POLYMERS PROD SENIOR TECHMCIAN 0 427 0 244 _ ! 0 61 ( i 1 1 I - 2 2
[ ......... _ ,
2EFLON POLYMERS PROD QUALITY COORD 0.444 j 0.444 0.444 € t 1 _ - _ 1 _ 2
TEFLON@ COPOLYMERS
PROD. TECH ASSOC_ 0.459 0.196 ¢ 0.715 2 E I _ _ - 3 2
TEFLON@ COPOLYMERS
PROD_ADMIN ASSISTANT 0.488 0.488 i 0 488 1 1 2
TEFLON POLYMERS PROD PROD N COORDINATOR 0.55 0 528 1 0 572 i 2i 2
!g E
? TEFLO POLYMERS PROD. SR TECH ASSOC Ov581 0.17 1.57 i 3 j 1 4 _ 2
. TECHNICAL SPECIALIST 0.635 0.61 0 659 E i .2 _ 2 2
i TEFLON@COPOLYMERS gp
( PROD. _ SPECIALIST 0.763 0.134 2.39 i4 2� 6 2
TEPLON@, POLYMERS PROD SR ENGINEER 0.765 [ 0.412 L59� .._ € _ 2 1 4 2
TECHNICAL w TECH SPEC A w.m 0.783 0.783 0.783 i w C 1 1 2
-P f -,- .-.. .._._ - .
TEFLON@ POLYMERS PROD 6810 ADVM OPR II 0 805 t 0 299 1 53 ' 2 17 4�
_ .. _ .-_ ....__._ ..._ ...... -. --.. ._ . _
. € .. ttt
' I'EFLON rD POLYMERS PROD 6810 TRNC OPR II 1 07 1 07 _ ; ] 07 ! I 1 .3
.. .. . .. - ._ _ _ ...._ . -
TEFLON@ COPOLYMERS
6910OPERATORII 1.136 0188 _ 5.015 j _ 18 j 12 19 1 50 - 3.
TEPLON POLYMhRS PROD .�SUPERVISOR1_21 -_, 0233- 1� 3. 4, 8 - 3
s
TEFLON POLYMERS PROD _ 6810 STC/SPS OP II _ _ 1.3 1 3 ; 1.3 ` ( 1 1 _ 31
TEFLON@ COPOLYMERS
_ y_____.......____._;_..._....___#_..__..�_ .... _....... -
PROD. . .. _.. .. _ .. .. ... _ .. .. .. ... -.
TEFLON MAINTENANCE 6720 MECHANIC 1726 I 0155 6.81 E 1 4 6 7 2 1-- 19 3
TEFLO, POLYMERS PROD 6810 OPERATOR 11 �3.311 L 0 199 $ 9.55 I 4 2 18 8 J 32
73 Of 73 (c) Copyright 2006 E.I. du Pont de Nemours and Company. All Rights Reserved. No portion of this work may be reproduced in whole or in part by any electronic,
mechanical or other means, including xerography, photocopy, or any information storage or retrieval system or otherwise distributed without the express written permission of DuPont.
DEQ-CFW 00001741